JP2009523834 | New lactam |
JP2010518113 | Polar hydrophilic prodrugs of amphetamines and other stimulants, and how to make and use them |
WO/2008/014311 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE |
BARROW JAMES (US)
WEI HUIJUN (US)
WO2007002433A1 | 2007-01-04 |
THAT WHICH IS CLAIMED: wherein: R1a and R2a are each independently selected from the group consisting of H and substituted or unsubstituted branched or straightchain C1-C4 alkyl, provided that at least one of R1a and R2a is H; R3a is H or halogen; R4a is selected from the group consisting of substituted or unsubstituted branched or straightchain C1-C4 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; La is selected from the group consisting of –(CH2)n–, –S(=O)2–, –C(=O)–(CH2)m–, –C(=O)–NH–, and –C(=O)–(CH2)p–O–; wherein n and p are each integers selected from 1, 2, 3, and 4; m is 0 or 1; and stereoisomers and pharmaceutically acceptable salts thereof. 2. The compound of claim 1, wherein R1a and R2a are each independently H or methyl, provided that at least one of R1a and R2a is H. 3. The compound of claim 1, wherein R3a is H or F. 4. The compound of claim 1, wherein R4a is selected from the group consisting of methyl, isopropyl, cyclopropyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, and substituted or unsubstituted pyrimidinyl. 5. The compound of claim 4, wherein the phenyl, pyridinyl, or pyrimidinyl is substituted with one or more substituent groups selected from the group consisting of substituted or unsubstituted branched or straightchain C1-C4 alkyl, C1-C4 alkoxyl, cyclopropyl, trifluoromethyl, hydroxyl, halogen, cyano, carbamoyl, and benzyloxy. 6. The compound of claim 4, wherein R4a is selected from the group consisting of 2-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 4-trifluoromethylphenyl, and 3,5-dichloropyridin-2-yl. 7. The compound of claim 1, wherein the compound of formula (IA) is selected from the group consisting of: 1'-((4-chlorophenyl)sulfonyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid; 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; methyl 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate; 1'-(2-(4-chlorophenyl)acetyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid; 1'-(4-chlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; 1'-(3,5-dichloropicolinoyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; 1'-((4-chlorophenyl)carbamoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid; 2-oxo-1'-(4-(trifluoromethyl)benzoyl)spiro[indoline-3,4'-piperidine]-5- carboxylic acid; 1'-(2-(4-chlorophenoxy)acetyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid; 1'-(cyclopropanecarbonyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; 1'-(4-chlorobenzoyl)-1-methyl-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid; 1'-acetyl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; 1'-isobutyryl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; 1'-(2-chlorobenzoyl)-2-oxospiro[indolineho-3,4'-piperidine]-5-carboxylic acid; 1'-(2-chlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; 1'-(2,4-dichlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; 1'-(2,4-dichlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid; 1'-((3,5-dichloropyridin-2-yl)methyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid; and stereoisomers and pharmaceutically acceptable salts thereof. 8. A compound of formula (IB): ; wherein: q is 0 or 1; A can be present or absent and when present is a 4-, 5-, or 6-membered cycloalkyl or cycloheteroalkyl ring; R1b is selected from the group consisting of H and substituted or unsubstituted branched or straightchain C1-C4 alkyl; R2b is H or –C(=O)–OR5b; R3b is selected from the group consisting of H, halogen, and –C(=O)–OR5b, wherein R5b is selected from the group consisting of H and substituted or unsubstituted branched or straightchain C1-C4 alkyl, provided that at least one of R1b and R5b is H; R4b is selected from the group consisting of substituted or unsubstituted branched or straightchain C1-C4 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; Lb is selected from the group consisting of –C(=O)–, –(CH2)r–, and –(CH2)s–O–; wherein r is selected from the group consisting of 1, 2, 3, or 4 and s is an integer selected from the group consisting of 0, 1, 2, or 3; and stereoisomers and pharmaceutically acceptable salts thereof. 9. The compound of claim 8, wherein the compound of formula (IB) is: 10. The compound of claim 9, wherein R1b and R5b are each H. 11. The compound of claim 9, wherein R3b is H or F. 12. The compound of claim 8, wherein A is present and is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, and cyclohexyl: wherein * indicates a point of attachment of ring A to a nitrogen atom in the 3- position of the 2,3-dihydro-1H-benzo[d]imidazole ring and ** indicates a point of attachment of ring A to linker Lb. 13. The compound of claim 8, wherein R4a is selected from the group consisting of methyl, isopropyl, cyclopropyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, and substituted or unsubstituted pyrimidinyl. 14. The compound of claim 13, wherein the phenyl, pyridinyl, or pyrimidinyl is substituted with one or more substituent groups selected from the group consisting of substituted or unsubstituted branched or straightchain C1-C4 alkyl, C1-C4 alkoxyl, cyclopropyl, trifluoromethyl, hydroxyl, halogen, cyano, carbamoyl, and benzyloxy. 15. The compound of claim 13, wherein R4b is halogen-substituted phenyl or halogen-substituted pyridyl. 16. The compound of claim 15, wherein R4b is selected from the group consisting of 2-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, and 3,5- dichloropyridin-2-yl. 17. The compound of claim 8, wherein the compound of formula (IB) is selected from the group consisting of: 3-(1-(2-chlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-(1-(2-chlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylic acid; 3-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-((1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylic acid; 3-(2-(4-chlorophenoxy)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylic acid; 3-(1-(2,4-dichlorobenzoyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-(1-(2,4-dichlorobenzyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; (S)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; (R)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 1-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; (S)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; (R)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 1-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-(3-((3,5-dichloropyridin-2-yl)oxy)propyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-((1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-((1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid; 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-6-fluoro-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylic acid; and stereoisomers and pharmaceutically acceptable salts thereof. 18. A method for treating a disease, condition, or disorder associated with IP6K, the method comprising administering a compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment. 19. The method of claim 18, wherein the disease, condition, or disorder is selected from the group consisting of a psychiatric disease, Alzheimer’s disease, and diabetes. 20. The method of claim 19, wherein the psychiatric disease is bipolar disorder. 21. The method of any one of claims 18-20, further comprising one or more of inhibiting IP6K, increasing AKT activity, and inhibiting GSK3 activity. |
Following long-standing patent law convention, the terms “a,” “an,” and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to “a subject” includes a plurality of subjects, unless the context clearly is to the contrary (e.g., a plurality of subjects), and so forth. Throughout this specification and the claims, the terms “comprise,” “comprises,” and “comprising” are used in a non-exclusive sense, except where the context requires otherwise. Likewise, the term “include” and its grammatical variants are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items. For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing amounts, sizes, dimensions, proportions, shapes, formulations, parameters, percentages, quantities, characteristics, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about” even though the term “about” may not expressly appear with the value, amount or range. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are not and need not be exact, but may be approximate and/or larger or smaller as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of ordinary skill in the art depending on the desired properties sought to be obtained by the presently disclosed subject matter. For example, the term “about,” when referring to a value can be meant to encompass variations of, in some embodiments, ± 100% in some embodiments ± 50%, in some embodiments ± 20%, in some embodiments ± 10%, in some embodiments ± 5%, in some embodiments ±1%, in some embodiments ± 0.5%, and in some embodiments ± 0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions. Further, the term “about” when used in connection with one or more numbers or numerical ranges, should be understood to refer to all such numbers, including all numbers in a range and modifies that range by extending the boundaries above and below the numerical values set forth. The recitation of numerical ranges by endpoints includes all numbers, e.g., whole integers, including fractions thereof, subsumed within that range (for example, the recitation of 1 to 5 includes 1, 2, 3, 4, and 5, as well as fractions thereof, e.g., 1.5, 2.25, 3.75, 4.1, and the like) and any range within that range. EXAMPLES The following Examples have been included to provide guidance to one of ordinary skill in the art for practicing representative embodiments of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill can appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter. The synthetic descriptions and specific examples that follow are only intended for the purposes of illustration and are not to be construed as limiting in any manner to make compounds of the disclosure by other methods. Synthesis of Representative Spirooxindole Acids of Formula (IA) Intermediate A: Methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride To a suspension of 1'-tert-butoxycarbonyl-2-oxospiro[indoline-3,4'-piperidine]- 5- carboxylic acid (766 mg, 2.21 mmol) in methanol (10 mL) at 0 °C was added thionyl chloride (1.9 mL, 26 mmol). The resulting mixture was allowed to reach room temperature with stirring for 18 h. The solvent was removed in vacuo to give methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (600 mg, 2.02 mmol, 91.4% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.03 (s, 1 H) 8.87 (br. s., 2 H) 7.91 (dd, J = 8.08, 1.77 Hz, 1 H) 7.80 (d, J = 1.52 Hz, 1 H) 7.01 (d, J = 8.34 Hz, 1 H) 3.84 (s, 3 H) 3.44 - 3.54 (m, 2 H) 3.29 (d, J = 13.14 Hz, 2 H) 2.11 - 2.21 (m, 2 H) 1.93 (d, J = 14.40 Hz, 2 H) LCMS: [M+1] = 261, rt = 1.40 min. Example 1: 1'-((4-chlorophenyl)sulfonyl)-2-oxospiro[indoline-3,4'-piper idine]-5- carboxylic acid Methyl 1'-(4-chlorophenyl)sulfonyl-2-oxospiro[indoline-3,4'-piperid ine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (50.0 mg, 0.169 mmol), 4-chlorobenzenesulfonyl chloride (39.1 mg, 0.185 mmol) in chloroform (5 mL) was added DIPEA (90.2 µL, 0.506 mmol). The resulting mixture was stirred at room temperature for 30 min. The solvent was removed with a stream of N2 and the residue triturated with water/MeOH (3:1) for 18 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-(4-chlorophenyl)sulfonyl-2-oxospiro[indoline-3,4'-piperid ine]-5-carboxylate (49.5 mg, 0.114 mmol, 67.5% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.83 (s, 1 H) 7.83 - 7.88 (m, 3 H) 7.77 - 7.82 (m, 2 H) 7.73 (s, 1 H) 6.93 (d, J = 8.34 Hz, 1 H) 3.81 (s, 3 H) 3.37 - 3.45 (m, 2 H) 3.23 (t, J = 9.35 Hz, 2 H) 1.92 - 2.02 (m, 2 H) 1.79 (d, J = 14.15 Hz, 2 H) LCMS: [M+1] = 435/437, rt = 1.32 min (lipophilic method). 1'-((4-chlorophenyl)sulfonyl)-2-oxospiro[indoline-3,4'-piper idine]-5-carboxylic acid A suspension of methyl 1'-(4-chlorophenyl)sulfonyl-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (49.5 mg, 0.114 mmol) and lithium hydroxide monohydrate (4.8 mg, 0.11 mmol) in THF (4 mL) and water (0.4 mL) was stirred at room temperature for 21 h, then at 40 °C for 28 h, then at 3 days at room temperature. The solvent was removed under a stream of N2, taken up in water, filtered through a syringe filter and acidified by addition of 6 N HCl. After stirring for 18 h, the solid was collected by filtration, washed with water and dried to give 1'-((4- chlorophenyl)sulfonyl)-2-oxospiro[indoline-3,4'-piperidine]- 5-carboxylic acid (38.4 mg, 0.0912 mmol, 80.2% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.70 (br. s., 1 H) 10.77 (s, 1 H) 7.71 - 7.87 (m, 6 H) 6.90 (d, J = 8.08 Hz, 1 H) 3.44 (d, J = 11.87 Hz, 2 H) 3.12 - 3.25 (m, 2 H) 1.97 (t, J = 10.36 Hz, 2 H) 1.79 (d, J = 13.90 Hz, 2 H) LCMS: [M+1] = 421/423, rt = 2.20 min. Example 2: 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid Methyl 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (52 mg, 0.175 mmol), 4-chlorobenzoic acid (30.2 mg, 0.193 mmol) and HBTU (73.1 mg, 0.193 mmol) in chloroform (5 mL) was added DIPEA (93.8 µL, 0.526 mmol). the resulting mixture was stirred at room temperature for 2.5 h. The solvent was removed with a stream of N2 and the residue triturated with water/MeOH (3:1) for 1 h. The solid was collected by filtration, washed with water and dried to give a solid which was purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 4 g silica gel cartridge) to give methyl 1'-(4-chlorobenzoyl)-2- oxospiro[indoline-3,4'-piperidine]-5-carboxylate (52.4 mg, 0.131 mmol, 74.9% yield) as a white gummy solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.86 (s, 1 H) 8.07 (d, J = 1.52 Hz, 1 H) 7.88 (dd, J = 8.21, 1.64 Hz, 1 H) 7.56 - 7.60 (m, 2 H) 7.51 - 7.55 (m, 2 H) 6.97 (d, J = 8.08 Hz, 1 H) 4.20 (br. s., 1 H) 3.83 (s, 3 H) 3.76 (d, J = 9.85 Hz, 2 H) 3.50 (br. s., 1 H) 1.94 - 2.04 (m, 2 H) 1.80 (br. s., 1 H) 1.66 (br. s., 1 H) LCMS: [M+1] = 399/401, rt = 2.34 min. 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid A suspension of methyl 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylate (52.4 mg, 0.131 mmol) and lithium hydroxide monohydrate (5.5 mg, 0.131 mmol) in THF (4 mL) and water (0.4 mL) was stirred at room temperature for 21 h, then at 40 °C for 21 h. The solvent was removed under a stream of N2 to give a residue which was taken up in water then filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 1 h. The solid was collected by filtration, washed with water and air-dried to give a residue which was purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid (4.7 mg, 0.012 mmol, 9.3% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.72 (br. s., 1 H) 10.82 (s, 1 H) 8.05 (s, 1 H) 7.86 (d, J = 8.08 Hz, 1 H) 7.55 - 7.59 (m, 2 H) 7.51 - 7.55 (m, 2 H) 6.94 (d, J = 8.08 Hz, 1 H) 4.17 (br. s., 1 H) 3.78 (t, J = 10.61 Hz, 2 H) 3.50 (br. s., 1 H) 1.90 - 2.01 (m, 2 H) 1.80 (br. s., 1 H) 1.67 (br. s., 1 H) LCMS: [M+1] = 385/387, rt = 2.04 min. Example 3: Methyl 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (51.8 mg, 0.175 mmol), 4-chlorobenzoic acid (30.1 mg, 0.192 mmol) and HBTU (72.8 mg, 0.192 mmol) in chloroform (5 mL) was added DIPEA (93.5 µL, 0.524 mmol). The resulting mixture was stirred at room temperature for 17 h. The solvent was removed with a stream of N2 and the residue triturated with water/MeOH (3:1) for 18 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-(4-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylate (63.0 mg, 0.158 mmol, 90.5% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.86 (s, 1 H) 8.07 (s, 1 H) 7.88 (d, J = 8.34 Hz, 1 H) 7.56 - 7.59 (m, 2 H) 7.51 - 7.55 (m, 2 H) 6.97 (d, J = 8.08 Hz, 1 H) 4.22 (br. s., 1 H) 3.83 (s, 3 H) 3.77 (br. s., 2 H) 3.50 (br. s., 1 H) 1.94 - 2.04 (m, 2 H) 1.77 (br. s., 1 H) 1.67 (br. s., 1 H) LCMS: [M+1] = 399/401, rt = 2.35 min. Example 4: 1'-(2-(4-chlorophenyl)acetyl)-2-oxospiro[indoline-3,4'-piper idine]-5- carboxylic acid Methyl 1'-(2-(4-chlorophenyl)acetyl)-2-oxospiro[indoline-3,4'-piper idine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (55.0 mg, 0.185 mmol), 4-chlorophenylacetic acid (34.8 mg, 0.204 mmol) and HBTU (77.3 mg, 0.204 mmol) in chloroform (5 mL) was added DIPEA (99.2 µL, 0.556 mmol). The resulting mixture was stirred at room temperature for 20 h. The solvent was removed with a stream of N 2 and the residue triturated with water/MeOH (3:1) for 18 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-[2-(4-chlorophenyl)acetyl]-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (49.5 mg, 0.120 mmol, 64.7% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.86 (s, 1 H) 7.85 - 7.90 (m, 2 H) 7.37 - 7.43 (m, 2 H) 7.29 - 7.34 (m, 2 H) 6.96 (d, J = 8.59 Hz, 1 H) 3.98 - 4.07 (m, 1 H) 3.75 - 3.89 (m, 7 H) 3.57 - 3.67 (m, 1 H) 1.64 - 1.80 (m, 4 H) LCMS: [M+1] = 413/415, rt = 1.19 min (lipophilic method). 1'-(2-(4-chlorophenyl)acetyl)-2-oxospiro[indoline-3,4'-piper idine]-5-carboxylic acid A suspension of methyl 1'-[2-(4-chlorophenyl)acetyl]-2-oxo-spiro[indoline-3,4'- piperidine]-5-carboxylate (49.5 mg, 0.120 mmol) and lithium hydroxide monohydrate (5.0 mg, 0.120 mmol) in THF (4 mL) and water (0.4 mL) was stirred at room temperature for 6 days. The solvent was removed with a stream of N 2 . The residue was taken up in water, filtered through a syringe filter, acidified by addition of 6 N HCl and stirred for 3 h. The solid was collected by filtration, washed with water and dried to give a yellow solid which was purified by automated normal-phase chromatography (0-15% MeOH/DCM, 4 g silica gel cartridge) to give 1'-[2-(4- chlorophenyl)acetyl]-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid (15.0 mg, 0.0376 mmol, 31.4% yield) as a colorless film. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.73 (br. s., 1 H) 10.82 (s, 1 H) 7.83 - 7.90 (m, 2 H) 7.37 - 7.42 (m, 2 H) 7.28 - 7.33 (m, 2 H) 6.94 (d, J = 7.83 Hz, 1 H) 3.91 - 4.04 (m, 1 H) 3.73 - 3.89 (m, 4 H) 3.60 - 3.71 (m, 1 H) 1.63 - 1.83 (m, 4 H) LCMS: [M+1] = 399/401, rt = 2.05 min. Example 5: 1'-(4-chlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5-c arboxylic acid Methyl 1'-(4-chlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5-c arboxylate A suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (56.5 mg, 0.190 mmol), 4-chlorobenzaldehyde (29.4 mg, 0.209 mmol) and sodium triacetoxyborohydride (121 mg, 0.571 mmol) in chloroform (5 mL) was stirred at room temperature for 26 h. The solvent was removed with a stream of N2 and the residue was partitioned between water and EtOAc. The solvent was removed from the organic layer with a stream of N2 to give a residue which was purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 1'-[(4-chlorophenyl)methyl]-2-oxo-spiro[indoline-3,4'- piperidine]-5-carboxylate acetate (72.0 mg, 0.162 mmol, 85.0% yield) as a colorless gum. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.02 (br. s., 1 H) 10.82 (s, 1 H) 7.96 (s, 1 H) 7.87 (d, J = 8.08 Hz, 1 H) 7.42 (s, 4 H) 6.96 (d, J = 8.08 Hz, 1 H) 3.83 (s, 3 H) 3.63 (s, 2 H) 2.83 (br. s., 2 H) 2.56 (br. s., 2 H) 1.92 (s, 3 H) 1.81 (br. s., 2 H) 1.71 (br. s., 2 H) LCMS: [M+1] = 385/387, rt = 2.01 min. 1'-(4-chlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5-c arboxylic acid To a solution of methyl 1'-[(4-chlorophenyl)methyl]-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate acetate (72.0 mg, 0.162 mmol) in methanol (5 mL) was added 1 N NaOH (485 µL, 0.485 mmol). The resulting mixture was stirred at room temperature for 18 h, then at 50 °C for 31 h. After cooling, 6 N HCl (27 µL, 1 eq.) was added and the solvent removed with a stream of N2 to give a residue which was purified by automated normal-phase chromatography (0-40% MeOH/DCM, 4 g silica gel cartridge) to give 1'-[(4-chlorophenyl)methyl]-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylic acid (29.1 mg, 0.0785 mmol, 48.5% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.79 (s, 1 H) 7.98 (s, 1 H) 7.86 (dd, J = 8.21, 1.64 Hz, 1 H) 7.37 - 7.46 (m, 4 H) 6.94 (d, J = 8.08 Hz, 1 H) 3.63 (br. s., 2 H) 2.84 (br. s., 2 H) 2.56 (br. s., 2 H) 1.78 - 1.88 (m, 2 H) 1.71 (br. s., 2 H) LCMS: [M+1] = 371/373, rt = 1.99 min. Example 6: 1'-(3,5-dichloropicolinoyl)-2-oxospiro[indoline-3,4'-piperid ine]-5- carboxylic acid Methyl 1'-(3,5-dichloropicolinoyl)-2-oxospiro[indoline-3,4'-piperid ine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (40.0 mg, 0.135 mmol), 3,5-dichloropyridine-2-carboxylic acid (28.5 mg, 0.148 mmol) and HBTU (56.2 mg, 0.148 mmol) in chloroform (5 mL) was added DIPEA (72.2 µL, 0.404 mmol). The resulting mixture was stirred at room temperature for 21 h. The solvent was removed with a stream of N2 and the residue triturated with water/MeOH (5:1) for 18 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-(3,5-dichloropicolinoyl)-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (29.2 mg, 0.0672 mmol, 49.9% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.93 (s, 1 H) 8.71 (d, J = 2.02 Hz, 1 H) 8.44 (d, J = 2.02 Hz, 1 H) 7.87 - 7.93 (m, 2 H) 6.99 (d, J = 8.08 Hz, 1 H) 4.10 - 4.22 (m, 1 H) 3.79 - 3.92 (m, 4 H) 3.63 - 3.74 (m, 1 H) 3.23 - 3.32 (m, 1 H) 1.69 - 1.96 (m, 4 H) LCMS: [M+1] = 434/436, rt = 2.22 min. 1'-(3,5-dichloropicolinoyl)-2-oxospiro[indoline-3,4'-piperid ine]-5-carboxylic acid To a solution of methyl 1'-(3,5-dichloropyridine-2-carbonyl)-2-oxo-spiro[indoline- 3,4'-piperidine]-5-carboxylate (29.2 mg, 0.0672 mmol) in methanol (5 mL) was added 1 N NaOH (135 µL, 0.135 mmol). The resulting mixture was stirred at room temperature for 22 h, then at 50 °C for 48 h. The solvent was removed with a stream of N2 to give a residue which was purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give 1'-(3,5- dichloropicolinoyl)-2-oxospiro[indoline-3,4'-piperidine]-5-c arboxylic acid (18.0 mg, 0.0428 mmol, 63.7% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.76 (br. s., 1 H) 10.89 (s, 1 H) 8.71 (d, J = 2.02 Hz, 1 H) 8.44 (d, J = 2.02 Hz, 1 H) 7.84 - 7.90 (m, 2 H) 6.96 (d, J = 8.34 Hz, 1 H) 4.09 - 4.20 (m, 1 H) 3.84 - 3.93 (m, 1 H) 3.63 - 3.73 (m, 1 H) 3.28 (d, J = 13.89 Hz, 1 H) 1.86 (d, J = 4.80 Hz, 2 H) 1.71 - 1.80 (m, 2 H) LCMS: [M+1] = 420/422/424, rt = 1.90 min.
Example 7: 1'-((4-chlorophenyl)carbamoyl)-2-oxospiro[indoline-3,4'-pipe ridine]- 5-carboxylic acid Methyl 1'-((4-chlorophenyl)carbamoyl)-2-oxospiro[indoline-3,4'-pipe ridine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (38.0 mg, 0.128 mmol) and 4-chlorophenyl isocyanate (20.6 mg, 0.135 mmol) was added DIPEA (45.7 µL, 0.256 mmol). The resulting mixture was stirred at room temperature for 3 h. The solvent was removed with a stream of N2 and the residue was triturated with water/MeOH (4:1) for 18 h. The solid was collected by filtration and dried to give methyl 1'-((4-chlorophenyl)carbamoyl)-2- oxospiro[indoline-3,4'-piperidine]-5-carboxylate (48.0 mg, 0.116 mmol, 90.6% yield) as a white solid, and was used without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 10.89 (s, 1 H) 8.73 (s, 1 H) 7.96 (d, J = 1.52 Hz, 1 H) 7.89 (dd, J = 8.08, 1.52 Hz, 1 H) 7.53 - 7.57 (m, 2 H) 7.28 - 7.33 (m, 2 H) 6.97 - 7.01 (m, 1 H) 3.77 - 3.85 (m, 7 H) 1.72 - 1.88 (m, 4 H) LCMS: [M+1] = 414/416, rt = 2.35 min. 1'-((4-chlorophenyl)carbamoyl)-2-oxospiro[indoline-3,4'-pipe ridine]-5-carboxylic acid A mixture of methyl 1'-[(4-chlorophenyl)carbamoyl]-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (48.0 mg, 0.116 mmol) and 1 N NaOH (232 µL, 0.232 mmol) was stirred at 50 °C for 75 h. The contents were acidified by addition of 6 N HCl, then the solvent was removed with a stream of N2. The residue which was purified by automated normal-phase chromatography (0-100% MeOH/DCM, 4 g silica gel cartridge) to give 1'-((4-chlorophenyl)carbamoyl)-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylic acid (5.5 mg, 0.014 mmol, 12% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.73 (br. s., 1 H) 10.85 (s, 1 H) 8.74 (s, 1 H) 7.93 (d, J = 1.52 Hz, 1 H) 7.87 (dd, J = 8.08, 1.52 Hz, 1 H) 7.52 - 7.57 (m, 2 H) 7.27 - 7.32 (m, 2 H) 6.96 (d, J = 8.08 Hz, 1 H) 3.81 (t, J = 5.68 Hz, 4 H) 1.71 - 1.86 (m, 4 H) LCMS: [M+1] = 400/402, rt = 2.03 min. Example 8: 2-oxo-1'-(4-(trifluoromethyl)benzoyl)spiro[indoline-3,4'-pip eridine]- 5-carboxylic acid Methyl 2-oxo-1'-(4-(trifluoromethyl)benzoyl)spiro[indoline-3,4'-pip eridine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (57.0 mg, 0.192 mmol), 4-(trifluoromethyl)benzoic acid (62.7 mg, 0.330 mmol) and HBTU (80.1 mg, 0.211 mmol) in Chloroform (5 mL) was added DIPEA (103 µL, 0.576 mmol). The resulting mixture was stirred at room temperature for 2 h. The solvent was removed with a stream of N 2 and the residue triturated with water/MeOH (9:1) for 18 h. The solid was collected by filtration, washed with water and dried to give methyl 2-oxo-1'-(4-(trifluoromethyl)benzoyl)spiro[indoline-3,4'- piperidine]-5-carboxylate (48.2 mg, 0.112 mmol, 58.0% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 10.88 (s, 1 H) 8.09 (s, 1 H) 7.88 (dd, J = 8.21, 1.64 Hz, 1 H) 7.83 - 7.86 (m, 2 H) 7.75 - 7.79 (m, 2 H) 6.97 (d, J = 8.08 Hz, 1 H) 4.27 (d, J = 12.63 Hz, 1 H) 3.83 (s, 3 H) 3.76 (d, J = 11.37 Hz, 2 H) 3.43 (d, J = 12.13 Hz, 1 H) 2.02 (d, J = 11.12 Hz, 2 H) 1.80 (d, J = 14.15 Hz, 1 H) 1.64 (d, J = 13.39 Hz, 1 H) 19 F NMR (376 MHz, DMSO- d6) δ ppm -161.04 (s, 3 F) LCMS: [M+1] = 433, rt = 2.44 min. 2-oxo-1'-(4-(trifluoromethyl)benzoyl)spiro[indoline-3,4'-pip eridine]-5-carboxylic acid To a solution of methyl 2-oxo-1'-(4-(trifluoromethyl)benzoyl)spiro[indoline-3,4'- piperidine]-5-carboxylate (48.2 mg, 0.112 mmol) in methanol (5 mL) was added 1 N NaOH (223 µL, 0.223 mmol). The resulting mixture was stirred at room temperature for 16 h, then at 50 °C for 79 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 2-oxo-1'-(4- (trifluoromethyl)benzoyl)spiro[indoline-3,4'-piperidine]-5-c arboxylic acid (32.4 mg, 0.0774 mmol, 69.5% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.72 (br. s., 1 H) 10.83 (s, 1 H) 8.06 (s, 1 H) 7.73 - 7.90 (m, 5 H) 6.94 (d, J = 8.08 Hz, 1 H) 4.22 (d, J = 11.62 Hz, 1 H) 3.77 (t, J = 12.00 Hz, 2 H) 3.43 (d, J = 13.14 Hz, 1 H) 1.98 (d, J = 10.86 Hz, 2 H) 1.80 (d, J = 13.39 Hz, 1 H) 1.65 (d, J = 14.15 Hz, 1 H) 19 F NMR (376 MHz, DMSO- d 6 ) δ ppm -161.05 (s, 3 F) LCMS: [M+1] = 419, rt = 2.14 min. Example 9: 1'-(2-(4-chlorophenoxy)acetyl)-2-oxospiro[indoline-3,4'-pipe ridine]- 5-carboxylic acid Methyl 1'-(2-(4-chlorophenoxy)acetyl)-2-oxospiro[indoline-3,4'-pipe ridine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (42.0 mg, 0.142 mmol), (4-chlorophenoxy)acetic acid (29.1 mg, 0.156 mmol) and HBTU (59.0 mg, 0.156 mmol) in chloroform (5 mL) was added DIPEA (75.8 µL, 0.425 mmol). The resulting mixture was stirred at room temperature for 2 h. The solvent was removed with a stream of N2 and the residue triturated with water/MeOH (7:1) for 4 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-[2-(4-chlorophenoxy)acetyl]-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (41.2 mg, 0.0961 mmol, 67.9% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 10.88 (s, 1 H) 7.93 (d, J = 1.52 Hz, 1 H) 7.88 (dd, J = 8.08, 1.77 Hz, 1 H) 7.32 - 7.37 (m, 2 H) 6.99 - 7.02 (m, 2 H) 6.97 (d, J = 8.08 Hz, 1 H) 4.88 - 5.00 (m, 2 H) 4.02 (d, J = 12.63 Hz, 1 H) 3.78 - 3.88 (m, 4 H) 3.68 - 3.76 (m, 1 H) 3.57 - 3.67 (m, 1 H) 2.02 (t, J = 9.85 Hz, 1 H) 1.67 - 1.83 (m, 3 H) LCMS: [M+1] = 429/431, rt = 2.40 min. 1'-(2-(4-chlorophenoxy)acetyl)-2-oxospiro[indoline-3,4'-pipe ridine]-5-carboxylic acid A suspension of methyl 1'-[2-(4-chlorophenoxy)acetyl]-2-oxo-spiro[indoline-3,4'- piperidine]-5-carboxylate (41.2 mg, 0.961 mmol) in methanol (5 mL) was treated with 1 N NaOH (192 µL, 0.192 mmol) and stirred at 50 °C for 102 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-(2-(4-chlorophenoxy)acetyl)-2-oxospiro[indoline-3,4'-pipe ridine]-5-carboxylic acid (16.4 mg, 0.0395 mmol, 41.2% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.69 (br. s., 1 H) 10.82 (br. s., 1 H) 7.92 (br. s., 1 H) 7.86 (d, J = 7.23 Hz, 1 H) 7.34 (d, J = 8.49 Hz, 2 H) 7.00 (d, J = 8.65 Hz, 2 H) 6.95 (d, J = 7.70 Hz, 1 H) 4.88 - 5.00 (m, 2 H) 3.97 (d, J = 12.42 Hz, 1 H) 3.84 (br. s., 1 H) 3.62 - 3.76 (m, 2 H) 1.99 (br. s., 1 H) 1.68 - 1.82 (m, 3 H) LCMS: [M+1] = 415/417, rt = 2.10 min. Example 10: 1'-(cyclopropanecarbonyl)-2-oxospiro[indoline-3,4'-piperidin e]-5- carboxylic acid Methyl 1'-(cyclopropanecarbonyl)-2-oxospiro[indoline-3,4'-piperidin e]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (45.4 mg, 0.153 mmol) in chloroform (5 mL) was added cyclopropanecarbonyl chloride (13.9 µL, 0.153 mmol) followed by DIPEA (81.9 µL, 0.459 mmol). The resulting mixture was stirred at room temperature for 90 min. The solvent was removed with a stream of N 2 and the residue triturated with water/MeOH (9:1) for 18 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-(cyclopropanecarbonyl)-2-oxospiro[indoline-3,4'-piperidin e]-5- carboxylate (39.2 mg, 0.119 mmol, 78.0% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.89 (s, 1 H) 7.96 (d, J = 1.52 Hz, 1 H) 7.89 (dd, J = 8.21, 1.64 Hz, 1 H) 6.98 (d, J = 8.34 Hz, 1 H) 3.93 - 4.05 (m, 3 H) 3.82 (s, 3 H) 3.67 (br. s., 1 H) 2.00 - 2.08 (m, 1 H) 1.88 (br. s., 1 H) 1.64 - 1.83 (m, 3 H) 0.83 (br. s., 1 H) 0.70 - 0.80 (m, 3 H) LCMS: [M+1] = 329, rt = 1.92 min. 1'-(cyclopropanecarbonyl)-2-oxospiro[indoline-3,4'-piperidin e]-5-carboxylic acid A suspension of methyl 1'-(cyclopropanecarbonyl)-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (39.2 mg, 0.119 mmol) in methanol (5 mL) was treated with 1 N NaOH (239 µL, 0.239 mmol) and stirred at 50 °C for 60 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-(cyclopropanecarbonyl)-2-oxospiro[indoline-3,4'-piperidin e]-5-carboxylic acid (28.3 mg, 0.0900 mmol, 75.4% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.68 (br. s., 1 H) 10.82 (br. s., 1 H) 7.93 (br. s., 1 H) 7.87 (d, J = 7.70 Hz, 1 H) 6.96 (d, J = 7.86 Hz, 1 H) 3.89 - 4.07 (m, 3 H) 3.71 (br. s., 1 H) 2.03 (br. s., 1 H) 1.66 - 1.92 (m, 4 H) 0.70 - 0.86 (m, 4 H) LCMS: [M+1] = 315, rt = 1.59 min. Example 11: 1'-(4-chlorobenzoyl)-1-methyl-2-oxospiro[indoline-3,4'-piper idine]- 5-carboxylic acid A suspension of sodium hydride (6.0 mg, 0.15 mmol) in THF (2 mL) was stirred at room temperature for 10 min, then a solution of methyl 1'-(4-chlorobenzoyl)-2- oxospiro[indoline-3,4'-piperidine]-5-carboxylate (50.0 mg, 0.125 mmol) and iodomethane (9.4 µL, 0.15 mmol) in THF (2 mL) was added portionwise over 5 min at room temperature and the resulting mixture stirred for 18 h. Added sodium hydride (6.0 mg, 0.15 mmol) and stirred an additional 24 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 2 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-(4- chlorobenzoyl)-1-methyl-2-oxo-spiro[indoline-3,4'-piperidine ]-5-carboxylic acid (44.3 mg, 0.111 mmol, 88.6% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.76 (br. s., 1 H) 8.09 (br. s., 1 H) 7.95 (d, J = 7.23 Hz, 1 H) 7.58 (d, J = 8.02 Hz, 2 H) 7.50 - 7.55 (m, 2 H) 7.14 (d, J = 8.17 Hz, 1 H) 4.22 (br. s., 1 H) 3.77 (br. s., 2 H) 3.51 (br. s., 1 H) 3.18 (s, 3 H) 1.95 - 2.05 (m, 2 H) 1.77 (br. s., 1 H) 1.65 (br. s., 1 H) LCMS: [M+1] = 413, rt = 2.22 min. Example 12: 1'-acetyl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid Methyl 1'-acetyl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (40.4 mg, 0.136 mmol) in chloroform (5 mL) was added acetyl chloride (9.7 µL, 0.136 mmol) followed by DIPEA (72.9 µL, 0.408 mmol). The resulting mixture was stirred at room temperature for 90 min. The solvent was removed with a stream of N2 and the residue triturated with water/MeOH (7:1) for 18 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-acetyl-2- oxospiro[indoline-3,4'-piperidine]-5-carboxylate (20.0 mg, 0.0662 mmol, 48.6% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.87 (s, 1 H) 7.95 (d, J = 1.52 Hz, 1 H) 7.88 (dd, J = 8.21, 1.64 Hz, 1 H) 6.97 (d, J = 8.08 Hz, 1 H) 3.99 (d, J = 12.63 Hz, 1 H) 3.82 (s, 4 H) 3.68 (d, J = 13.90 Hz, 1 H) 3.54 - 3.63 (m, 1 H) 2.08 (s, 3 H) 1.89 - 1.98 (m, 1 H) 1.62 - 1.79 (m, 3 H) LCMS: [M+1] = 303, rt = 1.72 min. 1'-acetyl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid A suspension of methyl 1'-acetyl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate (20.0 mg, 0.0662 mmol) in methanol (5 mL) was treated with 1 N NaOH (132 µL, 0.132 mmol) and stirred at 50 °C for 123 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 3 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-acetyl-2- oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid (10.1 mg, 0.0350 mmol, 52.9% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.67 (br. s., 1 H) 10.80 (br. s., 1 H) 7.92 (br. s., 1 H) 7.86 (d, J = 7.86 Hz, 1 H) 6.95 (d, J = 7.86 Hz, 1 H) 3.95 (br. d, J = 12.40 Hz, 1 H) 3.80 - 3.88 (m, 1 H) 3.60 - 3.71 (m, 2 H) 2.08 (s, 3 H) 1.87 - 1.95 (m, 1 H) 1.64 - 1.79 (m, 3 H) LCMS: [M+1] = 289, rt = 1.39 min. Example 13: 1'-isobutyryl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxy lic acid Methyl 1'-isobutyryl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxy lic acid To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (42.1 mg, 0.142 mmol) in chloroform (5 mL) was added isobutyryl chloride (14.9 µL, 0.142 mmol) followed by DIPEA (76.0 µL, 0.426 mmol). The resulting mixture was stirred at room temperature for 90 min. The solvent was removed with a stream of N 2 and the residue triturated with water/MeOH (9:1) for 42 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-(2-methylpropanoyl)-2-oxospiro[indoline-3,4'-piperidine]- 5-carboxylate (20.0 mg, 0.0605 mmol, 42.7% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 10.88 (s, 1 H) 7.95 (d, J = 1.52 Hz, 1 H) 7.89 (dd, J = 8.08, 1.77 Hz, 1 H) 6.98 (d, J = 8.34 Hz, 1 H) 3.98 (d, J = 13.64 Hz, 1 H) 3.86 (d, J = 9.85 Hz, 1 H) 3.82 (s, 3 H) 3.79 (br. s., 1 H) 3.65 (t, J = 8.72 Hz, 1 H) 2.93 (dt, J = 13.58, 6.73 Hz, 1 H) 1.82 - 1.92 (m, 1 H) 1.65 - 1.80 (m, 3 H) 1.05 (dd, J = 15.28, 6.69 Hz, 6 H) LCMS: [M+1] = 331, rt = 1.99 min. 1'-isobutyryl-2-oxospiro[indoline-3,4'-piperidine]-5-carboxy lic acid A suspension of methyl 1'-(2-methylpropanoyl)-2-oxospiro[indoline-3,4'-piperidine]- 5-carboxylate (20.0 mg, 0.0605 mmol) in methanol (5 mL) was treated with 1 N NaOH (242 µL, 0.242 mmol) and stirred at 50 °C for 96 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 3 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-(2- methylpropanoyl)-2-oxospiro[indoline-3,4'-piperidine]-5-carb oxylic acid (14.5 mg, 0.0458 mmol, 75.7% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.68 (br. s., 1 H) 10.82 (br. s., 1 H) 7.92 (br. s., 1 H) 7.86 (d, J = 7.70 Hz, 1 H) 6.96 (d, J = 7.39 Hz, 1 H) 3.85 - 3.98 (m, 2 H) 3.65 - 3.81 (m, 2 H) 2.89 - 2.98 (m, 1 H) 1.67 - 1.89 (m, 4 H) 1.06 (br. d, J = 10.80 Hz, 6 H) LCMS: [M+1] = 317, rt = 1.68 min. Example 14: 1'-(2-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid Methyl 1'-(2-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (50.0 mg, 0.169 mmol), 2-chlorobenzoic acid (29.0 mg, 0.185 mmol) and HBTU (70.3 mg, 0.185 mmol) in chloroform (5 mL) was added DIPEA (90.2 µL, 0.506 mmol). The resulting mixture was stirred at room temperature for 18 h. The solvent was removed with a stream of N 2 and the residue triturated with water/MeOH (5:1) for 18 h. The solid was collected by filtration, washed with water and dried to give methyl 1'-(2-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylate (50.0 mg, 0.125 mmol, 74.4% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 10.87 - 10.95 (m, 1 H) 7.65 - 8.09 (m, 3 H) 7.52 - 7.61 (m, 1 H) 7.42 - 7.50 (m, 2 H) 6.93 - 7.02 (m, 1 H) 4.13 - 4.35 (m, 1 H) 3.83 (s, 3 H) 3.61 - 3.79 (m, 2 H) 3.23 (d, J = 13.39 Hz, 1 H) 1.60 - 2.10 (m, 5 H) LCMS: [M+1] = 399/401, rt = 2.27 min. 1'-(2-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid To a solution of methyl 1'-(2-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylate (50.0 mg, 0.125 mmol) in methanol (8 mL) was added 1 N NaOH (376 µL, 0.376 mmol). The resulting mixture was stirred at 50 °C for 48 h. The solvent was removed with a stream of N 2 and the residue was taken up in water, filtered through a syringe filter and acidified by addition of 6 N HCl. After stirring for 18 h, the solid was collected by filtration and dried to give a beige solid which was further purified by automated normal-phase chromatography (0-40% MeOH/DCM, 20 g silica gel cartridge) to give 1'-(2-chlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid (38.8 mg, 0.101 mmol, 80.4% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.74 (br. s., 1 H) 10.83 - 10.89 (m, 1 H) 7.81 - 8.06 (m, 2 H) 7.42 - 7.70 (m, 4 H) 6.92 - 6.98 (m, 1 H) 4.13 - 4.29 (m, 1 H) 3.61 - 3.93 (m, 2 H) 3.19 - 3.32 (m, 1 H) 1.62 - 2.05 (m, 4 H) LCMS: [M+1] = 385, rt = 1.95 min. Example 15: 1'-(2-chlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5- carboxylic acid Methyl 1'-(2-chlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5-c arboxylate A suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (47.0 mg, 0.158 mmol), 2-chlorobenzaldehyde (19.6 µL, 0.174 mmol) and sodium triacetoxyborohydride (101 mg, 0.475 mmol) in CHCl 3 (5 mL) was stirred at room temperature for 5 days (for convenience) The contents were treated with 5% Na 2 CO 3 and extracted with CHCl 3 (3x) and passed through a cotton plug. The solvent was removed with a stream of N2 to give a residue which was purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 1'-[(2-chlorophenyl)methyl]-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (46.3 mg, 0.120 mmol, 76.0% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.83 (s, 1 H) 7.98 (d, J = 1.26 Hz, 1 H) 7.88 (dd, J = 8.08, 1.77 Hz, 1 H) 7.60 (dd, J = 7.58, 1.77 Hz, 1 H) 7.46 (dd, J = 7.83, 1.26 Hz, 1 H) 7.37 (td, J = 7.45, 1.52 Hz, 1 H) 7.28 - 7.34 (m, 1 H) 6.97 (d, J = 8.08 Hz, 1 H) 3.83 (s, 3 H) 3.72 (s, 2 H) 2.91 (ddd, J = 11.49, 7.58, 3.66 Hz, 2 H) 2.59 - 2.69 (m, 2 H) 1.80 - 1.88 (m, 2 H) 1.70 - 1.79 (m, 2 H) LCMS: [M+1] = 385/387, rt = 1.91 min. 1'-(2-chlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine]-5-c arboxylic acid To a suspension of methyl 1'-[(2-chlorophenyl)methyl]-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (46.3 mg, 0.120 mmol) in methanol (5 mL) was added 1 N NaOH (602 µL, 0.602 mmol). The resulting mixture was stirred at 60 °C for 22 h. After cooling, the solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was carefully neutralized by addition of 2 N HCl and stirred for 3 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-[(2-chlorophenyl)methyl]-2- oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid (3.2 mg, 0.0086 mmol, 7.2% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.71 (br. s., 1 H) 10.78 (br. s., 1 H) 8.00 (br. s., 1 H) 7.86 (d, J = 6.82 Hz, 1 H) 7.62 (br. s., 1 H) 7.45 (d, J = 7.58 Hz, 1 H) 7.27 - 7.40 (m, 2 H) 6.95 (d, J = 7.33 Hz, 1 H) 3.72 (br. s., 2 H) 2.91 (br. s., 2 H) 2.64 (br. s., 2 H) 1.66 - 1.90 (m, 4 H) LCMS: [M+1] = 371/373, rt = 1.69 min. Example 16: 1'-(2,4-dichlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine] -5- carboxylic acid Methyl 1'-(2,4-dichlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine] -5- carboxylate A suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (41.4 mg, 0.140 mmol), 2,4-dichlorobenzaldehyde (26.9 mg, 0.154 mmol) and sodium triacetoxyborohydride (88.7 mg, 0.419 mmol) in CHCl 3 (5 mL) was stirred at room temperature for 4 days (for convenience). The contents were treated with 5% Na2CO3 and extracted with CHCl3 (3x) and passed through a cotton plug. The solvent was removed with a stream of N 2 to give a residue which was purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 1'-[(2,4-dichlorophenyl)methyl]-2-oxospiro[indoline- 3,4'-piperidine]-5-carboxylate (44.8 mg, 0.107 mmol, 76.6% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 10.83 (s, 1 H) 7.98 (d, J = 1.52 Hz, 1 H) 7.88 (dd, J = 8.08, 1.52 Hz, 1 H) 7.62 - 7.65 (m, 2 H) 7.45 (dd, J = 8.34, 2.27 Hz, 1 H) 6.97 (d, J = 8.08 Hz, 1 H) 3.83 (s, 3 H) 3.70 (s, 2 H) 2.90 (td, J = 7.58, 3.54 Hz, 2 H) 2.63 (dt, J = 7.39, 3.76 Hz, 2 H) 1.80 - 1.87 (m, 2 H) 1.71 - 1.79 (m, 2 H) LCMS: [M+1] = 419/421/423, rt = 2.07 min. 1'-(2,4-dichlorobenzyl)-2-oxospiro[indoline-3,4'-piperidine] -5-carboxylic acid To a suspension of methyl 1'-[(2,4-dichlorophenyl)methyl]-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (44.8 mg, 0.107 mmol) in methanol (5 mL) was added 1 N NaOH (534 µL, 0.534 mmol). The resulting mixtures was stirred at 50 °C for 22 h. After cooling, the solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was carefully neutralized by addition of 2 N HCl and stirred for 3 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-[(2,4-dichlorophenyl)methyl]-2- oxospiro[indoline-3,4'-piperidine]-5-carboxylic acid (38.0 mg, 0.0938 mmol, 87.8% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.72 (br. s., 1 H) 10.79 (s, 1 H) 7.99 (s, 1 H) 7.86 (dd, J = 8.08, 1.52 Hz, 1 H) 7.61 - 7.66 (m, 2 H) 7.45 (dd, J = 8.34, 2.27 Hz, 1 H) 6.94 (d, J = 8.08 Hz, 1 H) 3.70 (s, 2 H) 2.89 (d, J = 7.83 Hz, 2 H) 2.63 (br. s., 2 H) 1.83 (d, J = 8.08 Hz, 2 H) 1.74 (br. s., 2 H) LCMS: [M+1] = 405/407/409, rt = 1.88 min. Example 17: 1'-(2,4-dichlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine ]-5- carboxylic acid Methyl 1'-(2,4-dichlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine ]-5- carboxylate To a suspension of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (41.0 mg, 0.138 mmol), 2,4-dichlorobenzoic acid (29.0 mg, 0.152 mmol) and HBTU (57.6 mg, 0.152 mmol) in CHCl3 (5 mL) was added DIPEA (74.0 µL, 0.415 mmol). The resulting mixture was stirred at room temperature for 7 days (for convenience). The contents were treated with water and extracted with CHCl3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 1'-(2,4-dichlorobenzoyl)-2- oxospiro[indoline-3,4'-piperidine]-5-carboxylate (50.5 mg,0.117 mmol, 84.4% yield) as an off white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.85 - 10.91 (m, 1 H) 7.47 - 8.08 (m, 5 H) 6.94 - 7.00 (m, 1 H) 4.13 - 4.33 (m, 1 H) 3.63 - 3.89 (m, 5 H) 3.19 - 3.29 (m, 1 H) 1.59 - 2.10 (m, 4 H) LCMS: [M+1] = 433/435/437, rt = 2.53 min. 1'-(2,4-dichlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine ]-5-carboxylic acid To a suspension of methyl 1'-(2,4-dichlorobenzoyl)-2-oxospiro[indoline-3,4'- piperidine]-5-carboxylate (50.5 mg, 0.117 mmol) in methanol (5 mL) was added 1 N NaOH (583 µL, 0.583 mmol). The resulting mixture was stirred at 50 °C for 24 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 3 days. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-(2,4-dichlorobenzoyl)-2-oxospiro[indoline-3,4'-piperidine ]- 5-carboxylic acid (33.8 mg, 0.0806 mmol, 69.2% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.70 (br. s., 1 H) 10.79 - 10.87 (m, 1 H) 7.46 - 8.06 (m, 5 H) 6.90 - 6.98 (m, 1 H) 4.11 - 4.29 (m, 1 H) 3.62 - 3.92 (m, 2 H) 3.20 - 3.29 (m, 1 H) 1.60 - 2.06 (m, 4 H) LCMS: [M+1] = 419/421/423, rt = 2.18 min. Example 18: 1'-((3,5-dichloropyridin-2-yl)methyl)-2-oxospiro[indoline-3, 4'- piperidine]-5-carboxylic acid Methyl 1'-((3,5-dichloropyridin-2-yl)methyl)-2-oxospiro[indoline-3, 4'- piperidine]-5-carboxylate A mixture of methyl 2-oxospiro[indoline-3,4'-piperidine]-5-carboxylate hydrochloride (48.8 mg, 0.164 mmol), 3,5-dichloropyridine-2-carboxaldehyde (17.5 µL, 0.181 mmol) and sodium triacetoxyborohydride (104.6 mg, 0.493 mmol) in CHCl3 (5 mL) was stirred at room temperature for 6 days (for convenience) The contents were treated with 10% Na2CO3 and extracted with CHCl3 (3x) and passed through a cotton plug. The solvent was removed with a stream of N 2 to give a residue which was purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 1'-[(3,5-dichloro-2-pyridyl)methyl]-2-oxospiro[indoline- 3,4'-piperidine]-5-carboxylate (25.0 mg, 0.0595 mmol, 36.2% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.80 (s, 1 H) 8.63 (d, J = 2.20 Hz, 1 H) 8.25 (d, J = 2.20 Hz, 1 H) 7.98 (s, 1 H) 7.87 (dd, J = 8.17, 1.73 Hz, 1 H) 6.96 (d, J = 8.17 Hz, 1 H) 3.87 (s, 2 H) 3.83 (s, 3 H) 2.90 - 2.96 (m, 2 H) 2.72 - 2.80 (m, 2 H) 1.76 - 1.84 (m, 2 H) 1.61 - 1.69 (m, 2 H) LCMS: [M+1] = 434/436/438, rt = 1.94 min. 1'-((3,5-dichloropyridin-2-yl)methyl)-2-oxospiro[indoline-3, 4'-piperidine]-5- carboxylic acid To a suspension of methyl 1'-[(3,5-dichloro-2-pyridyl)methyl]-2-oxospiro[indoline- 3,4'-piperidine]-5-carboxylate (25.0 mg, 0.0595 mmol) in methanol (5 mL) was added 1 N NaOH (297 µL, 0.297 mmol). The resulting mixture was stirred at 60 °C for 24 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1'-[(3,5-dichloro-2-pyridyl)methyl]-2-oxospiro[indoline-3,4' - piperidine]-5-carboxylic acid hydrochloride (12.1mg,0.0273mmol, 45.948% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.77 (br. s., 1 H) 10.90 - 11.10 (m, 1 H) 10.08 - 10.52 (m, 1 H) 8.76 - 8.89 (m, 1 H) 8.36 - 8.49 (m, 2 H) 7.86 - 7.96 (m, 1 H) 7.81 (s, 1 H) 6.94 - 7.05 (m, 1 H) 4.77 - 5.03 (m, 2 H) 3.55 - 3.86 (m, 4 H) 1.92 - 2.30 (m, 2 H) LCMS: [M+1] = 406/408/410, rt = 1.71 min. Synthesis of Representative Benzimidazolones of Formula (IB) Intermediate A: Methyl 2-oxo-3-(piperidin-4-yl)-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate hydrochloride tert-butyl 4-((5-(methoxycarbonyl)-2-nitrophenyl)amino)piperidine-1- carboxylate A mixture of methyl 3-fluoro-4-nitrobenzoate (302 mg, 1.52 mmol), tert-butyl 4- aminopiperidine-1-carboxylate (364 mg, 1.82 mmol) and cesium carbonate (593 mg, 1.82 mmol) in acetonitrile (10 mL) was stirred at room temperature for 90 h. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO4, filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 20 g silica gel cartridge) to give tert-butyl 4-((5-(methoxycarbonyl)-2- nitrophenyl)amino)piperidine-1-carboxylate (440 mg, 1.16 mmol, 76.5% yield) as a yellow-orange solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.19 (d, J = 8.84 Hz, 1 H) 7.90 (d, J = 8.08 Hz, 1 H) 7.60 (d, J = 1.52 Hz, 1 H) 7.17 (dd, J = 8.84, 1.77 Hz, 1 H) 3.84 - 3.98 (m, 6 H) 3.02 (br. s., 2 H) 1.94 (d, J = 10.36 Hz, 2 H) 1.44 - 1.55 (m, 2 H) 1.42 (s, 9 H) LCMS: [M-1+23] = 402, rt = 1.90 min (lipophilic method). tert-butyl 4-((2-amino-5-(methoxycarbonyl)phenyl)amino)piperidine-1- carboxylate To a solution of tert-butyl 4-((5-(methoxycarbonyl)-2-nitrophenyl)amino)piperidine- 1-carboxylate (440 mg, 1.16 mmol) in EtOAc (20 mL) was added 10% Pd/C (40 mg). The resulting suspension was placed under an atmosphere of H 2 via a balloon and stirred at room temperature for 18 h. The contents were filtered through Celite and the solvent removed in vacuo to give tert-butyl 4-((2-amino-5- (methoxycarbonyl)phenyl)amino)piperidine-1-carboxylate (400 mg, 1.145 mmol, 98.7% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.14 (dd, J = 8.08, 1.77 Hz, 1 H) 7.04 (d, J = 1.77 Hz, 1 H) 6.55 (d, J = 8.08 Hz, 1 H) 5.42 - 5.48 (m, 2 H) 4.41 (d, J = 7.58 Hz, 1 H) 3.89 (d, J = 10.11 Hz, 2 H) 3.72 (s, 3 H) 3.39 - 3.50 (m, 1 H) 2.94 (br. s., 2 H) 1.91 (d, J = 10.11 Hz, 2 H) 1.41 (s, 9 H) 1.21 - 1.33 LCMS: [M-1+23] = 350, rt = 1.14 min (lipophilic method). Methyl 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylate To a solution of tert-butyl 4-((2-amino-5-(methoxycarbonyl)phenyl)amino)piperidine- 1-carboxylate (247 mg, 0.708 mmol) in chloroform (5 mL) was added 1,1'- carbonyldiimidazole (172 mg, 1.06 mmol). The resulting mixture was stirred at 50 °C for 18 h. Added 1,1'-carbonyldiimidazole (86 mg, 0.53 mmol) and stirred at 50 °C for 18 h. The solvent was removed under a stream of N 2 , and the residue was purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 4 g silica gel cartridge) to give methyl 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (220 mg, 0.586 mmol, 82.8% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.36 (s, 1 H) 7.72 (d, J = 1.26 Hz, 1 H) 7.69 (dd, J = 8.08, 1.52 Hz, 1 H) 7.09 (d, J = 8.08 Hz, 1 H) 4.39 - 4.49 (m, 1 H) 4.01 - 4.14 (m, 2 H) 3.83 (s, 3 H) 2.91 (br. s., 2 H) 2.11 - 2.24 (m, 2 H) 1.71 (d, J = 10.11 Hz, 2 H) 1.45 (s, 9 H) LCMS: [M-1]+23 = 398, rt = 2.44 min Methyl 2-oxo-3-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride To a suspension of methyl 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (220 mg, 0.586 mmol) in methanol (5 mL) was added 6 N HCl (977 µL, 5.86 mmol). The resulting mixture was stirred at 60 °C for 4 h. The solvent was removed in vacuo to give methyl 2-oxo-3-(piperidin-4- yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate hydrochloride (188 mg,0.605 mmol, 103% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.43 (s, 1 H) 9.03 (d, J = 11.37 Hz, 1 H) 8.67 (d, J = 8.59 Hz, 1 H) 7.90 (s, 1 H) 7.71 (dd, J = 8.08, 1.52 Hz, 1 H) 7.11 (d, J = 8.08 Hz, 1 H) 4.59 (ddd, J = 12.13, 8.08, 3.79 Hz, 1 H) 3.85 (s, 3 H) 3.42 (d, J = 11.87 Hz, 2 H) 3.05 - 3.15 (m, 2 H) 2.53 - 2.64 (m, 2 H) 1.89 (d, J = 11.87 Hz, 2 H) LCMS: [M+1] = 276, rt = 1.46 min Example 1: 3-(1-(2-chlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid Methyl 3-(1-(2-chlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl 2-oxo-3-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride (30.0 mg, 0.0962 mmol), 2-chlorobenzoic acid (15.1 mg, 0.0962 mmol), HBTU (36.5 mg, 0.0962 mmol) and DIPEA (17.2 µL, 0.0962 mmol) in chloroform (5 mL) was stirred at room temperature for 41 h. The solvent was removed with a stream of N2 and the residue was purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 4 g silica gel cartridge) to give methyl 3- (1-(2-chlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H-ben zo[d]imidazole-5- carboxylate (30.1 mg, 0.0727 mmol, 75.6% yield) as an off-white solid. Two amide isomers seen by 1H NMR -- one peak by LCMS. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.35 - 11.40 (m, 1 H) 7.75 - 7.83 (m, 1 H) 7.68 - 7.72 (m, 1 H) 7.54 - 7.62 (m, 1 H) 7.37 - 7.50 (m, 3 H) 7.06 - 7.12 (m, 1 H) 4.52 - 4.76 (m, 2 H) 3.83 - 3.87 (m, 3 H) 3.57 - 3.68 (m, 1 H) 3.22 - 3.31 (m, 1 H) 3.10 - 3.19 (m, 1 H) 2.94 - 3.05 (m, 1 H) 2.14 - 2.43 (m, 3 H) 1.87 (d, J = 10.36 Hz, 1 H) 1.64 - 1.75 (m, 1 H) LCMS: [M+1] = 414/416, rt = 2.20 min. 3-(1-(2-chlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H-b enzo[d]imidazole-5- carboxylic acid To a solution of methyl 3-(1-(2-chlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate (29.0 mg, 0.0701 mmol) in methanol (5 mL) was added 1 N NaOH (210 µL, 0.210 mmol). The resulting mixture was stirred at 60 °C for 72 h. After cooling, the solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 3 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-(1-(2-chlorobenzoyl)piperidin-4-yl)-2- oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid (12.9 mg, 0.0323 mmol, 46.0% yield) as an off-white solid. Two amide conformers seen by 1 H NMR – one peak by LCMS. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.79 (br. s., 1 H) 11.30 - 11.33 (m, 1 H) 7.75 - 7.82 (m, 1 H) 7.67 (dd, J = 8.21, 1.39 Hz, 1 H) 7.53 - 7.60 (m, 1 H) 7.35 - 7.50 (m, 3 H) 7.04 - 7.09 (m, 1 H) 4.64 - 4.76 (m, 1 H) 4.51 - 4.64 (m, 1 H) 3.21 - 3.39 (m, 2 H) 2.93 - 3.04 (m, 1 H) 2.15 - 2.43 (m, 2 H) 1.87 (d, J = 11.62 Hz, 1 H) 1.69 (br. s., 1 H) LCMS: [M+1] = 400/402, rt = 1.88 min. Example 2: 3-(1-(2-chlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid Methyl 3-(1-(2-chlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl 2-oxo-3-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride (41.0 mg, 0.132 mmol), 2-chlorobenzaldehyde (16.3 µL, 0.145 mmol) and sodium triacetoxyborohydride (83.6 mg, 0.395 mmol) in chloroform (5 mL) was stirred at room temperature for 4 days (for convenience). The contents were treated with 5% Na 2 CO 3 and extracted with CHCl 3 (3x) and passed through a cotton plug. The solvent was removed with a stream of N2 to give a residue which was purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 3-(1-(2-chlorobenzyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (42.4 mg, 0.106 mmol, 80.6% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.35 (s, 1 H) 7.76 (d, J = 1.26 Hz, 1 H) 7.69 (dd, J = 8.08, 1.52 Hz, 1 H) 7.56 (dd, J = 7.58, 1.77 Hz, 1 H) 7.46 (dd, J = 7.71, 1.39 Hz, 1 H) 7.38 (td, J = 7.39, 1.39 Hz, 1 H) 7.28 - 7.34 (m, 1 H) 7.09 (d, J = 8.34 Hz, 1 H) 4.19 - 4.29 (m, 1 H) 3.85 (s, 3 H) 3.64 (s, 2 H) 2.98 (d, J = 10.61 Hz, 2 H) 2.31 - 2.43 (m, 2 H) 2.21 - 2.30 (m, 2 H) 1.69 (d, J = 11.62 Hz, 2 H) LCMS: [M+1] = 400/402, rt = 1.91 min. 3-(1-(2-chlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H-be nzo[d]imidazole-5- carboxylic acid To a suspension of methyl 3-(1-(2-chlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylate (42.4 mg, 0.106 mmol) in methanol (5 mL) was added 10% NaOH (382 µL, 1.06 mmol). The resulting mixture was stirred at 50 °C for 42 h. The solvent was removed with a stream of N 2 and the residue dissolved in water. The solution was acidified first by addition of 6 N HCl (177 µL, 1.06 mmol), then by careful dropwise addition of 6 N HCl. Once a precipitate appeared the mixture was allowed to stir for 2 h as the amount of precipitate increased. The solid was collected by filtration then dried under vacuum to give 3-(1-(2- chlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]im idazole-5-carboxylic acid hydrochloride (33.2 mg, 0.0786 mmol, 74.1% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.79 (br. s., 1 H) 11.40 (s, 1 H) 10.26 (br. s., 1 H) 7.86 (br. s., 2 H) 7.69 (d, J = 8.08 Hz, 1 H) 7.64 (d, J = 7.33 Hz, 1 H) 7.48 - 7.58 (m, 2 H) 7.08 (d, J = 8.08 Hz, 1 H) 4.55 - 4.66 (m, 1 H) 4.50 (d, J = 4.29 Hz, 2 H) 3.56 (d, J = 11.87 Hz, 2 H) 3.33 - 3.44 (m, 2 H) 2.70 (d, J = 13.39 Hz, 2 H) 1.95 (d, J = 11.12 Hz, 2 H) LCMS: [M+1] = 386/388, rt = 1.66 min. Example 3: 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylic acid Methyl 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylate A mixture of methyl 2-oxo-3-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride (36.4 mg, 0.117 mmol), 2,4-dichlorobenzoic acid (22.3 mg, 0.117 mmol), HBTU (44.3 mg, 0.117 mmol) and DIPEA (20.8 µL, 0.117 mmol) in chloroform (5 mL) was stirred at room temperature for 42 h. The solvent was removed with a stream of N2 and the residue which was purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 4 g silica gel cartridge) to give methyl 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylate (45.0 mg, 0.100 mmol, 86.0% yield) as a colorless gum. Two amide isomers seen by 1H NMR -- one peak by LCMS 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.32 - 11.37 (m, 1 H) 7.73 - 7.82 (m, 2 H) 7.70 (dd, J = 8.17, 1.26 Hz, 1 H) 7.52 - 7.59 (m, 1 H) 7.41 - 7.50 (m, 1 H) 7.06 - 7.12 (m, 1 H) 4.52 - 4.73 (m, 2 H) 3.83 - 3.87 (m, 3 H) 3.23 - 3.40 (m, 2 H) 2.94 - 3.04 (m, 1 H) 2.15 - 2.39 (m, 2 H) 1.87 (d, J = 12.42 Hz, 1 H) 1.65 - 1.75 (m, 1 H) LCMS: [M+1] = 448/450/452, rt = 2.43 min. 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylic acid To a solution of methyl 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylate (45.0 mg, 0.100 mmol) in methanol (5 mL) was added 1 N NaOH (502 µL, 0.502 mmol). The resulting mixture was stirred at 60 °C for 51 h. After cooling, the solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)- 2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid (25.7 mg, 0.0592 mmol, 59.0% yield) as a white solid. Two amide isomers seen by 1H NMR -- one peak by LCMS. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.71 (s, 1 H) 11.26 - 11.30 (m, 1 H) 7.40 - 7.82 (m, 5 H) 7.03 - 7.09 (m, 1 H) 4.63 - 4.74 (m, 1 H) 4.50 - 4.63 (m, 1 H) 3.22 - 3.40 (m, 2 H) 2.94 - 3.04 (m, 1 H) 2.15 - 2.38 (m, 2 H) 1.87 (d, J = 11.63 Hz, 1 H) 1.71 (d, J = 11.16 Hz, 1 H) LCMS: [M+1] = 434/436/438, rt = 2.09 min. Example 4: 3-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylic acid Methyl 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylate A mixture of methyl 2-oxo-3-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride (35.3 mg, 0.113 mmol), 2,4-dichlorobenzaldehyde (17.5 µL, 0.125 mmol) and Sodium triacetoxyborohydride (72.0 mg, 0.340 mmol) in chloroform (5 mL) was stirred at room temperature for 3 days (for convenience) The contents were treated with 5% Na 2 CO 3 and extracted with CHCl 3 (3x) and passed through a cotton plug. The solvent was removed with a stream of N2 to give a residue which was purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 3-(1-(2,4- dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d ]imidazole-5- carboxylate (22.9 mg, 0.0527 mmol, 46.6% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.32 (br. s., 1 H) 7.75 (d, J = 1.10 Hz, 1 H) 7.68 (dd, J = 8.17, 1.41 Hz, 1 H) 7.61 (d, J = 2.04 Hz, 1 H) 7.57 (d, J = 8.33 Hz, 1 H) 7.47 (dd, J = 8.25, 2.12 Hz, 1 H) 7.08 (d, J = 8.17 Hz, 1 H) 4.19 - 4.27 (m, 1 H) 3.85 (s, 3 H) 3.62 (s, 2 H) 2.96 (d, J = 11.00 Hz, 2 H) 2.32 - 2.42 (m, 2 H) 2.22 - 2.30 (m, 2 H) 1.70 (d, J = 12.73 Hz, 2 H) LCMS: [M+1] = 434/436/438, rt = 2.07 min. 3-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 3-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (22.9 mg, 0.0527 mmol) in methanol (5 mL) was added 1 N NaOH (264 µL, 0.264 mmol). the resulting mixture was stirred at 60 °C for 58 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-(1-(2,4-dichlorobenzyl)piperidin-4-yl)- 2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid hydrochloride (16.6 mg, 0.0363 mmol, 68.9% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.75 (br. s., 1 H) 11.35 (s, 1 H) 10.14 (br. s., 1 H) 7.81 - 7.87 (m, 3 H) 7.62 - 7.71 (m, 2 H) 7.07 (d, J = 8.02 Hz, 1 H) 4.58 (t, J = 12.03 Hz, 1 H) 4.48 (d, J = 4.24 Hz, 2 H) 3.57 (d, J = 11.00 Hz, 2 H) 2.61 - 2.74 (m, 2 H) 1.95 (d, J = 11.95 Hz, 2 H) LCMS: [M+1] = 420/422/424, rt = 1.85 min. Example 5: 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-ox o-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylic acid (1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexan-1-amine To a solution of trans-4-aminocyclohexanol (520 mg, 4.52 mmol) in DMF (20 mL) was added 60 % sodium hydride (542 mg, 13.6 mmol). The resulting mixture was stirred for 1 h, then 3,5-dichloro-2-fluoro-pyridine (899 mg, 5.42 mmol) was added. The contents were stirred for 4 h, then diluted with EtOAc. The organic layer was washed with 5% Na2CO3 (1x), water (3x), brine (1x), dried over MgSO4, filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-100% MeOH/DCM, 40 g silica gel cartridge) to give (1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexan-1-amine (316.9 mg, 1.214 mmol, 26.9% yield) as a brown syrup. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.20 (d, J = 2.27 Hz, 1 H) 8.15 (d, J = 2.53 Hz, 1 H) 4.94 (tt, J = 10.42, 4.11 Hz, 1 H) 2.64 (tt, J = 10.23, 3.66 Hz, 1 H) 1.99 - 2.07 (m, 2 H) 1.80 (dd, J = 13.14, 2.78 Hz, 2 H) 1.40 - 1.51 (m, 2 H) 1.11 - 1.22 (m, 2 H) LCMS: [M+1] = 261/263/265, rt = 2.02 min. Methyl 3-(((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)amin o)-4- nitrobenzoate A mixture of methyl 3-fluoro-4-nitro-benzoate (100 mg, 0.502 mmol), (1r,4r)-4-((3,5- dichloropyridin-2-yl)oxy)cyclohexan-1-amine (157 mg, 0.603 mmol) and cesium carbonate (196 mg, 0.603 mmol) in MeCN (5 mL) was stirred at 50 °C for 24 h, then at 30 °C for 3 days. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO4, filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 20 g silica gel cartridge) to give methyl 3-(((1r,4r)-4-((3,5- dichloropyridin-2-yl)oxy)cyclohexyl)amino)-4-nitrobenzoate (151 mg, 0.343 mmol, 68.2% yield) as an orange solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.22 (d, J = 2.36 Hz, 1 H) 8.19 (d, J = 8.96 Hz, 1 H) 8.17 (d, J = 2.36 Hz, 1 H) 7.93 (d, J = 7.86 Hz, 1 H) 7.61 (d, J = 1.41 Hz, 1 H) 7.16 (dd, J = 8.88, 1.65 Hz, 1 H) 5.05 - 5.12 (m, 1 H) 3.83 - 3.91 (m, 4 H) 2.05 - 2.16 (m, 4 H) 1.68 - 1.78 (m, 2 H) 1.57 - 1.67 (m, 2 H) LCMS: [M-1+23] = 440/442/444, rt = 2.87 min (lipophilic method). Methyl 4-amino-3-(((1r,4r)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)amino)benzoate A mixture of methyl 3-(((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)amin o)- 4-nitrobenzoate (151 mg, 0.343 mmol), zinc powder (224 mg, 3.43 mmol) and ammonium chloride (183 mg, 3.43 mmol) in ethanol (3 mL) and water (3 mL) was stirred at 80 °C for 1 h. The contents were diluted with EtOAc, filtered through Celite and the solvent removed in vacuo to give methyl 4-amino-3-(((1r,4r)-4-((3,5- dichloropyridin-2-yl)oxy)cyclohexyl)amino)benzoate (149 mg ,0.362 mmol, 105% yield) as a yellow solid. This material was used without further purification. 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.21 (d, J = 2.36 Hz, 1 H) 8.16 (d, J = 2.36 Hz, 1 H) 7.13 (dd, J = 8.10, 1.49 Hz, 1 H) 7.04 (s, 1 H) 6.55 (d, J = 8.02 Hz, 1 H) 5.45 (br. s., 2 H) 5.00 - 5.08 (m, 1 H) 4.40 (d, J = 5.82 Hz, 1 H) 3.73 (s, 4 H) 3.34 - 3.39 (m, 1 H) 2.11 - 2.18 (m, 2 H) 2.07 (d, J = 10.85 Hz, 2 H) 1.57 - 1.67 (m, 2 H) 1.33 - 1.43 (m, 2 H) LCMS: [M+1] = 410/412/414, rt = 1.48 min (lipophilic method). Methyl 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-ox o-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylate A mixture of methyl 4-amino-3-(((1r,4r)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)amino)benzoate (149 mg, 0.362 mmol) and 1,1'- carbonyldiimidazole (117 mg, 0.724 mmol) in chloroform (5 mL) was stirred at 60 °C for 18 h. The reaction mixture was reduced in volume with a stream of N 2 and purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 20 g silica gel cartridge) to give methyl 3-((1r,4r)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate (94.4 mg, 0.216 mmol, 59.7% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.31 (s, 1 H) 8.25 (d, J = 2.36 Hz, 1 H) 8.18 (d, J = 2.36 Hz, 1 H) 7.82 (s, 1 H) 7.69 (dd, J = 8.17, 1.41 Hz, 1 H) 7.08 (d, J = 8.17 Hz, 1 H) 5.08 - 5.16 (m, 1 H) 4.31 - 4.40 (m, 1 H) 3.85 (s, 3 H) 2.30 - 2.42 (m, 2 H) 2.23 (d, J = 10.06 Hz, 2 H) 1.83 (d, J = 11.63 Hz, 2 H) 1.66 - 1.78 (m, 2 H) LCMS: [M+1] = 436/438/440, rt = 1.81 min (lipophilic method). 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-ox o-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2- oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (94.4 mg, 0.216 mmol) in methanol (8 mL) was added 1 N NaOH (1.08 mL, 1.08 mmol). the resulting mixture was stirred at 60 °C for 24 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 3 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-((1r,4r)-4-((3,5- dichloropyridin-2-yl)oxy)cyclohexyl)-2-oxo-2,3-dihydro-1H-be nzo[d]imidazole-5- carboxylic acid (64.4 mg, 0.153 mmol, 70.5% yield) as a tan solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.62 (br. s, 1 H) 11.27 (s, 1 H) 8.25 (d, J = 2.36 Hz, 1 H) 8.17 (d, J = 2.36 Hz, 1 H) 7.80 (s, 1 H) 7.67 (dd, J = 8.17, 1.41 Hz, 1 H) 7.06 (d, J = 8.17 Hz, 1 H) 5.08 - 5.17 (m, 1 H) 4.30 - 4.40 (m, 1 H) 2.29 - 2.41 (m, 2 H) 2.23 (d, J = 11.16 Hz, 2 H) 1.84 (d, J = 11.48 Hz, 2 H) 1.66 - 1.77 (m, 2 H) LCMS: [M+1] = 422/424/426, rt = 1.35 min (lipophilic method). Example 6: 3-((1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-ox o-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylic acid (1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexan-1-amine To a solution of cis-4-aminocyclohexanol hydrochloride (250 mg, 1.65 mmol) in DMF (15mL) was added 60% sodium hydride (264 mg, 6.60 mmol) portionwise over 10 min. The resulting mixture was stirred for 15 min, then 3,5-dichloro-2-fluoro- pyridine (328 mg, 1.98 mmol) was added. The contents were stirred for 16 h, then diluted with EtOAc. The organic layer was washed with 5% Na2CO3 (1x), water (3x), brine (1x), dried over MgSO 4 , filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-100% MeOH/DCM, 20 g silica gel cartridge) to give (1s,4s)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexan-1-amine (168.7 mg, 0.646 mmol, 39.2% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.18 (d, J = 2.36 Hz, 1 H) 8.14 (d, J = 2.36 Hz, 1 H) 5.15 (d, J = 2.67 Hz, 1 H) 2.69 - 2.76 (m, 1 H) 1.91 (dt, J = 8.84, 4.46 Hz, 2 H) 1.54 - 1.66 (m, 4 H) 1.37 - 1.46 (m, 2 H) LCMS: [M+1] = 261/263/265, rt = 2.02 min. Methyl 3-(((1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)amin o)-4- nitrobenzoate A mixture of methyl 3-fluoro-4-nitro-benzoate (105 mg, 0.527 mmol), (1s,4s)-4-((3,5- dichloropyridin-2-yl)oxy)cyclohexan-1-amine (165 mg, 0.633 mmol) and cesium carbonate (206 mg, 0.633 mmol) in MeCN (5 mL) was stirred at 60 °C for 20 h. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO4, filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-50% EtOAc/heptane, 20 g silica gel cartridge) to give methyl 3-(((1s,4s)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)amino)-4-nitrobenzoate (196.2 mg ,0.446 mmol, 84.5% yield) as an orange foam. 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.17 - 8.22 (m, 3 H) 8.01 (d, J = 7.70 Hz, 1 H) 7.60 (d, J = 1.41 Hz, 1 H) 7.17 (dd, J = 8.88, 1.65 Hz, 1 H) 5.27 (br. s., 1 H) 3.87 - 3.94 (m, 4 H) 1.93 (br. s., 6 H) 1.71 - 1.81 (m, 2 H) LCMS: [M-1+23] = 440/442/444, rt = 2.84 min (lipophilic method). Methyl 4-amino-3-(((1s,4s)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)amino)benzoate A mixture of methyl 3-(((1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)amin o)- 4-nitrobenzoate (196 mg, 0.445 mmol), zinc powder (291 mg, 4.45 mmol) and ammonium chloride (238 mg, 4.45 mmol) in ethanol (3 mL) and water (3 mL) was stirred at 80 °C for 2 h. The contents were diluted with EtOAc, filtered through Celite and the solvent removed in vacuo to give methyl 4-amino-3-(((1s,4s)-4-((3,5- dichloropyridin-2-yl)oxy)cyclohexyl)amino)benzoate (177 mg, 0.431 mmol, 96.8% yield) as a pink foam. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.21 (d, J = 2.36 Hz, 1 H) 8.16 (d, J = 2.36 Hz, 1 H) 7.12 (dd, J = 8.17, 1.73 Hz, 1 H) 7.03 (s, 1 H) 6.54 (d, J = 8.17 Hz, 1 H) 5.48 - 5.53 (m, 2 H) 5.25 (br. s., 1 H) 4.45 (d, J = 7.07 Hz, 1 H) 3.72 (s, 3 H) 3.39 (d, J = 7.07 Hz, 1 H) 1.97 - 2.04 (m, 2 H) 1.76 - 1.88 (m, 4 H) 1.62 - 1.71 (m, 2 H) LCMS: [M+1] = 410/412/414, rt = 1.43 min (lipophilic method). Methyl 3-((1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-ox o-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylate A mixture of methyl 4-amino-3-(((1s,4s)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)amino)benzoate (176 mg, 0.429 mmol) and 1,1'- carbonyldiimidazole (139 mg, 0.858 mmol) in chloroform (8 mL) was stirred at 60 °C for 4 h. The solvent was removed under a stream of N2, and the residue triturated with MeOH for 1 h and cooled to 0 °C. The solid was collected by filtration, washed with cold MeOH and dried to give methyl 3-((1s,4s)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate (144.3 mg, 0.331 mmol, 77.1% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.35 (s, 1 H) 8.23 (s, 2 H) 7.88 (s, 1 H) 7.70 (dd, J = 8.17, 1.26 Hz, 1 H) 7.10 (d, J = 8.17 Hz, 1 H) 5.42 (br. s., 1 H) 4.38 - 4.46 (m, 1 H) 3.84 (s, 3 H) 2.40 - 2.48 (m, 2 H) 2.10 (d, J = 14.15 Hz, 2 H) 1.80 - 1.90 (m, 2 H) 1.63 (d, J = 12.10 Hz, 2 H) LCMS: [M+1] = 436/438/440, rt = 1.79 min (lipophilic method). 3-((1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-ox o-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 3-((1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2- oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (144.3 mg, 0.331 mmol) in methanol (5 mL) was added 1 N NaOH (1.65 mL, 1.65 mmol). The resulting mixture was stirred at 60 °C for 6 h, at 40 °C for 65 h, then at 60 °C for 26 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-((1s,4s)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-2-ox o-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylic acid (119.8 mg, 0.284 mmol, 85.8% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.72 (br. s., 1 H) 11.31 (s, 1 H) 8.21 - 8.24 (m, 1 H) 8.19 (d, J = 2.27 Hz, 1 H) 7.92 (s, 1 H) 7.67 (dd, J = 8.21, 1.39 Hz, 1 H) 7.07 (d, J = 8.08 Hz, 1 H) 5.44 (br. s., 1 H) 4.35 - 4.47 (m, 1 H) 2.42 - 2.54 (m, 2 H) 2.08 (d, J = 12.88 Hz, 2 H) 1.78 - 1.92 (m, 2 H) 1.63 (d, J = 11.87 Hz, 2 H) LCMS: [M+1] = 422/424/426, rt = 1.22 min (lipophilic method). Example 7: 3-( -4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-6-fluoro-2- oxo-2,3-dihydr o-1H-benzo[d]imidazole-5-carboxylic acid Methyl 3-(((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)amin o)-2-fluoro-4- nitrobenzoate A mixture of methyl 2,5-difluoro-4-nitrobenzoate (110 mg, 0.507 mmol), (1r,4r)-4- ((3,5-dichloropyridin-2-yl)oxy)cyclohexan-1-amine (159 mg, 0.608 mmol) and cesium carbonate (198 mg, 0.608 mmol) in MeCN (5 mL) was stirred at 30 °C for 8 days. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO 4 , filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 20 g silica gel cartridge) to give methyl 3-(((1r,4r)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)amino)-2-fluoro-4-nitrobenzoate (80.0 mg, 0.175 mmol, 34.5% yield) as an orange solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.23 (d, J = 2.27 Hz, 1 H) 8.19 (d, J = 2.27 Hz, 1 H) 8.02 (d, J = 10.86 Hz, 1 H) 7.79 (d, J = 8.08 Hz, 1 H) 7.52 (d, J = 5.81 Hz, 1 H) 5.09 (d, J = 9.09 Hz, 1 H) 3.90 (s, 3 H) 3.82 (br. s., 1 H) 2.02 - 2.16 (m, 4 H) 1.54 - 1.77 (m, 4 H) 19 F NMR (376 MHz, DMSO-d 6 ) δ ppm -229.08 (dd, J = 10.33, 5.74 Hz, 1 F) LCMS: [M-1+23] = 458/460/462, rt = 2.67 min (lipophilic method). Methyl 4-amino-3-(((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohe xyl)amino)-2- fluorobenzoate A mixture of methyl 3-(((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)amin o)- 2-fluoro-4-nitrobenzoate (80.0 mg, 0.175 mmol), zinc powder (114 mg, 1.75 mmol) and ammonium chloride (93.4 mg, 1.75 mmol) in ethanol (3 mL) and water (3 mL) was stirred at 80 °C for 2 h. The contents were diluted with EtOAc, filtered through Celite and the solvent removed in vacuo to give methyl 4-amino-3-(((1r,4r)-4-((3,5- dichloropyridin-2-yl)oxy)cyclohexyl)amino)-2-fluorobenzoate (89.0 mg, 0.208 mmol, 119% yield) as a dark red gum and was used without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.22 (d, J = 2.27 Hz, 1 H) 8.17 (d, J = 2.53 Hz, 1 H) 7.21 (br. s., 1 H) 6.87 (d, J = 7.07 Hz, 1 H) 6.33 (d, J = 13.39 Hz, 1 H) 5.86 (s, 2 H) 4.98 - 5.08 (m, 1 H) 4.32 (d, J = 7.07 Hz, 1 H) 3.73 (s, 3 H) 3.20 - 3.30 (m, 1 H) 2.13 (d, J = 9.09 Hz, 2 H) 2.05 (d, J = 10.36 Hz, 2 H) 1.53 - 1.66 (m, 2 H) 1.29 - 1.42 (m, 2 H) 19 F NMR (376 MHz, DMSO-d6) δ ppm -220.67 (dd, J = 13.20, 7.46 Hz, 1 F) LCMS: [M+1] = 428/430/432, rt = 1.46 min (lipophilic method). Methyl 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-6-fl uoro-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate A mixture of methyl 4-amino-3-(((1r,4r)-4-((3,5-dichloropyridin-2- yl)oxy)cyclohexyl)amino)-2-fluorobenzoate (89.0 mg, 0.208 mmol) and 1,1'- carbonyldiimidazole (33.7 mg, 0.208 mmol) in chloroform (6 mL) was stirred at 60 °C for 17 h. The solvent was removed with a stream of N 2 and the residue purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 12 g silica gel cartridge) to give methyl 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-6- fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (38.7 mg, 0.0852 mmol, 41.0% yield) as a pale orange solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.47 (br. s., 1 H) 8.25 (d, J = 2.27 Hz, 1 H) 8.19 (d, J = 2.27 Hz, 1 H) 7.70 (d, J = 5.81 Hz, 1 H) 6.94 (d, J = 10.86 Hz, 1 H) 5.07 - 5.17 (m, 1 H) 4.34 (t, J = 12.63 Hz, 1 H) 3.85 (s, 3 H) 2.30 - 2.37 (m, 2 H) 2.22 (d, J = 10.86 Hz, 2 H) 1.82 (d, J = 10.86 Hz, 2 H) 1.70 (q, J = 11.45 Hz, 2 H) 19 F NMR (376 MHz, DMSO-d6) δ ppm -217.01 (br. s., 1 F) LCMS: [M+1] = 454/456/458, rt = 1.71 min (lipophilic method). 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-6-fl uoro-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylic acid A mixture of methyl 3-((1r,4r)-4-((3,5-dichloropyridin-2-yl)oxy)cyclohexyl)-6- fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (38.7 mg, 0.0852 mmol) and lithium hydroxide monohydrate (3.6 mg, 0.0852 mmol) in THF (4 mL) and water (1 mL) was stirred at 60 °C for 46 h. The solvent was removed with a stream of N2, and the residue taken up in water. The solution was acidified by addition of 6 N HCl and stirred for 3 days (for convenience). The solid was collected by filtration, washed with water and dried under vacuum to give 3-((1r,4r)-4-((3,5- dichloropyridin-2-yl)oxy)cyclohexyl)-6-fluoro-2-oxo-2,3-dihy dro-1H- benzo[d]imidazole-5-carboxylic acid (35.6 mg, 0.0809 mmol, 94.9% yield) as a tan solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.99 (br. s., 1 H) 11.41 (s, 1 H) 8.26 (d, J = 2.53 Hz, 1 H) 8.19 (d, J = 2.53 Hz, 1 H) 7.68 (d, J = 5.81 Hz, 1 H) 6.90 (d, J = 10.86 Hz, 1 H) 5.06 - 5.17 (m, 1 H) 4.33 (br. s., 1 H) 2.32 (d, J = 13.39 Hz, 2 H) 2.22 (d, J = 10.86 Hz, 2 H) 1.82 (d, J = 13.39 Hz, 2 H) 1.63 - 1.76 (m, 2 H) 19 F NMR (376 MHz, DMSO-d 6 ) δ ppm -216.89 (br. s., 1 F) LCMS: [M+23] = 462/464/466, parent 277, rt = 1.31 min (lipophilic method). - Methyl 3-((2-(4-chlorophenoxy)ethyl)amino)-4-nitrobenzoate A mixture of methyl 3-fluoro-4-nitrobenzoate (100 mg, 0.502 mmol), 2-(4- chlorophenoxy)ethan-1-amine (103 mg, 0.603 mmol) and cesium carbonate (229 mg, 0.703 mmol) in MeCN (10 mL) was stirred at 60 °C for 18 h. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO 4 , filtered and the solvent removed in vacuo to give a residue which was purified by automated normal- phase chromatography (0-50% EtOAc/heptane, 12 g silica gel cartridge) to give methyl 3-((2-(4-chlorophenoxy)ethyl)amino)-4-nitrobenzoate (150 mg, 0.428 mmol, 85.2% yield) as an orange solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.33 (t, J = 5.74 Hz, 1 H) 8.18 (d, J = 8.80 Hz, 1 H) 7.71 (d, J = 1.57 Hz, 1 H) 7.30 - 7.36 (m, 2 H) 7.18 (dd, J = 8.88, 1.65 Hz, 1 H) 6.96 - 7.01 (m, 2 H) 4.26 (t, J = 5.27 Hz, 2 H) 3.89 (s, 3 H) 3.81 (q, J = 5.50 Hz, 2 H) LCMS: [M-1+23] = 351/353, rt = 1.97 min (lipophilic method). Methyl 4-amino-3-((2-(4-chlorophenoxy)ethyl)amino)benzoate To a solution of methyl 3-((2-(4-chlorophenoxy)ethyl)amino)-4-nitrobenzoate (150 mg, 0.428 mmol) in ethyl acetate (20 mL) was added 10% Pd / C (20.mg, 0.4300 mmol). the resulting suspension was stirred under a H 2 atmosphere (balloon) for 4 h. An 85:15 mix of desired product and des-chloro byproduct was seen by LCMS. The contents were filtered through Celite and the solvent removed in vacuo to give a pale yellow solid which was purified by automated normal-phase chromatography (0- 100% EtOAc/heptane, 12 g silica gel cartridge) to give methyl 4-amino-3-((2-(4- chlorophenoxy)ethyl)amino)benzoate (49.2 mg, 0.153 mmol, 35.9% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.31 - 7.36 (m, 2 H) 7.18 (dd, J=8.10, 1.81 Hz, 1 H) 7.06 (d, J=1.57 Hz, 1 H) 6.99 - 7.03 (m, 2 H) 6.56 (d, J=8.17 Hz, 1 H) 5.47 (s, 2 H) 4.84 (t, J=5.42 Hz, 1 H) 4.18 (t, J=5.42 Hz, 2 H) 3.73 (s, 3 H) 3.45 (q, J=5.34 Hz, 2 H) LCMS: [M+1] = 321, rt = 1.33 min (lipophilic method). Methyl 3-(2-(4-chlorophenoxy)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]im idazole-5- carboxylate A mixture of methyl 4-amino-3-((2-(4-chlorophenoxy)ethyl)amino)benzoate (49.2 mg, 0.153 mmol) and 1,1'-carbonyldiimidazole (49.7 mg, 0.307 mmol) in chloroform (5 mL) was stirred at 60 °C for 4 h. The solvent was removed under a stream of N 2 , and the residue triturated with MeOH for 18 h. The solid was collected by filtration, washed with cold MeOH and dried to give methyl 3-(2-(4-chlorophenoxy)ethyl)-2- oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (30.0 mg, 0.0865 mmol, 56.4% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.37 (s, 1 H) 7.83 (d, J = 1.26 Hz, 1 H) 7.67 - 7.71 (m, 1 H) 7.27 - 7.33 (m, 2 H) 7.08 (d, J = 8.34 Hz, 1 H) 6.86 - 6.92 (m, 2 H) 4.24 (s, 4 H) 3.85 (s, 3 H) LCMS: [M+1] = 347/349, rt = 1.29 min (lipophilic method). 3-(2-(4-chlorophenoxy)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]im idazole-5- carboxylic acid To a suspension of methyl 3-(2-(4-chlorophenoxy)ethyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate (30.0 mg, 0.0865 mmol) in methanol (5 mL) was added 1 N NaOH (433 µL, 0.433 mmol). The resulting mixture was stirred at 60 °C for 1 h, at 40 °C for 65 h, then at 60 °C for 24 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-(2-(4- chlorophenoxy)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole- 5-carboxylic acid (24.4 mg, 0.0733 mmol, 84.8% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.71 (br. s., 1 H) 11.31 (s, 1 H) 7.84 (d, J = 1.26 Hz, 1 H) 7.67 (dd, J = 8.34, 1.52 Hz, 1 H) 7.26 - 7.32 (m, 2 H) 7.05 (d, J = 8.34 Hz, 1 H) 6.85 - 6.92 (m, 2 H) 4.24 (s, 4 H) LCMS: [M+1] = 333, rt = 1.03 min (lipophilic method). Example 9: 3-(3-((3,5-dichloropyridin-2-yl)oxy)propyl)-2-oxo-2,3-dihydr o-1H- benzo[d]imidazole-5-carboxylic acid Methyl 3-((3-((3,5-dichloropyridin-2-yl)oxy)propyl)amino)-4-nitrobe nzoate A mixture of methyl 3-fluoro-4-nitrobenzoate (177 mg, 0.889 mmol), 3-((3,5- dichloropyridin-2-yl)oxy)propan-1-amine (236 mg, 1.07 mmol) and Cesium carbonate (348 mg, 1.07 mmol) in MeCN (15 mL) was stirred at 70 °C for 3 h. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO4, filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-25% EtOAc/heptane, 20 g silica gel cartridge) to give methyl 3-((3-((3,5-dichloropyridin-2- yl)oxy)propyl)amino)-4-nitrobenzoate (270 mg, 0.675 mmol, 75.9% yield) as a yellow-orange solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.27 (t, J = 5.68 Hz, 1 H) 8.15 - 8.19 (m, 3 H) 7.53 (d, J = 1.77 Hz, 1 H) 7.13 (dd, J = 8.84, 1.77 Hz, 1 H) 4.44 (t, J = 6.06 Hz, 2 H) 3.86 (s, 3 H) 3.59 (q, J = 6.48 Hz, 2 H) 2.13 (t, J = 6.32 Hz, 2 H) LCMS: [M+1] = 400/402/404, rt = 2.16 min (lipophilic method). Methyl 4-amino-3-((3-((3,5-dichloropyridin-2-yl)oxy)propyl)amino)be nzoate A mixture of methyl 3-((3-((3,5-dichloropyridin-2-yl)oxy)propyl)amino)-4- nitrobenzoate (270 mg, 0.675 mmol), zinc powder (441 mg, 6.75 mmol) and ammonium chloride (361 mg, 6.75 mmol) in ethanol (3 mL) and water (3 mL) was stirred at 80 °C for 3 h. The contents were diluted with EtOAc, filtered through Celite and the solvent removed in vacuo to give methyl 4-amino-3-((3-((3,5-dichloropyridin- 2-yl)oxy)propyl)amino)benzoate (309 mg, 0.835 mmol, 123% yield) as a tan solid. This material was carried forward without further purification. 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.22 (d, J = 2.53 Hz, 1 H) 8.19 (d, J = 2.27 Hz, 1 H) 7.16 (dd, J = 8.08, 1.77 Hz, 1 H) 6.98 (d, J = 1.77 Hz, 1 H) 6.54 (d, J = 8.08 Hz, 1 H) 5.46 (s, 2 H) 4.70 (t, J = 5.43 Hz, 1 H) 4.47 (t, J = 6.32 Hz, 2 H) 3.18 - 3.26 (m, 2 H) 2.09 (t, J = 6.44 Hz, 2 H) LCMS: [M+1] = 370/372/374, rt = 1.31 min (lipophilic method). Methyl 3-(3-((3,5-dichloropyridin-2-yl)oxy)propyl)-2-oxo-2,3-dihydr o-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl 4-amino-3-((3-((3,5-dichloropyridin-2- yl)oxy)propyl)amino)benzoate (250 mg, 0.675 mmol) and 1,1'-carbonyldiimidazole (219 mg, 1.35 mmol) in chloroform (8 mL) was stirred at 60 °C for 22 h. The solvent was removed with a stream of N2 and the residue triturated with water/MeOH (1:1) for 18 h. The solvent was collected by filtration, washed with water and dried under vacuum to give methyl 3-(3-((3,5-dichloropyridin-2-yl)oxy)propyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (263 mg, 0.665 mmol, 98.4% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.32 (s, 1 H) 8.17 (d, J = 2.02 Hz, 1 H) 8.13 (d, J = 2.27 Hz, 1 H) 7.65 (dd, J = 8.21, 1.64 Hz, 1 H) 7.60 (d, J = 1.52 Hz, 1 H) 7.07 (d, J = 8.34 Hz, 1 H) 4.32 (t, J = 5.81 Hz, 2 H) 4.02 (t, J = 6.44 Hz, 2 H) 3.79 (s, 3 H) 2.14 (quin, J = 6.13 Hz, 2 H) LCMS: [M+1] = 396/398/400, rt = 1.32 min (lipophilic method). 3-(3-((3,5-dichloropyridin-2-yl)oxy)propyl)-2-oxo-2,3-dihydr o-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 3-(3-((3,5-dichloropyridin-2-yl)oxy)propyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (263 mg, 0.665 mmol) in methanol (10 mL) was added 1 N NaOH (6.65 mL, 6.65 mmol). The resulting mixture was stirred at 60 °C for 18 h. After cooling, the solvent volume was reduced with a stream of N2 and the contents acidified by addition of 6 N HCl. The precipitate was collected by filtration, washed with water and dried under vacuum to give 3-(3-((3,5- dichloropyridin-2-yl)oxy)propyl)-2-oxo-2,3-dihydro-1H-benzo[ d]imidazole-5- carboxylic acid (217 mg, 0.568 mmol, 85.5% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.64 (br. s., 1 H) 11.25 (s, 1 H) 8.14 - 8.15 (m, 1 H) 8.13 - 8.14 (m, 1 H) 7.64 (td, J = 4.29, 1.52 Hz, 2 H) 7.04 (d, J = 8.34 Hz, 1 H) 4.34 (t, J = 5.94 Hz, 2 H) 4.01 (t, J = 6.69 Hz, 2 H) 2.13 (t, J = 6.19 Hz, 2 H) LCMS: [M+1] = 382/384/386, rt = 1.07 min (lipophilic method). Intermediate B: Methyl 3-(azetidin-3-yl)-2-oxo-2,3-dihydro- - benzo[d]imidazole-5-carboxylate hydrochloride tert-butyl 3-((5-(methoxycarbonyl)-2-nitrophenyl)amino)azetidine-1-carb oxylate A mixture of methyl 3-fluoro-4-nitro-benzoate (307 mg, 1.54 mmol), tert-butyl 3- aminoazetidine-1-carboxylate (319 mg, 1.85 mmol) and cesium carbonate (603 mg, 1.85 mmol) in MeCN (5 mL) was stirred at 30 °C for 4 days, then at 60 °C for 6 h. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO 4 , filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-50% EtOAc/heptane, 20 g silica gel cartridge) to give tert-butyl 3-((5-(methoxycarbonyl)-2- nitrophenyl)amino)azetidine-1-carboxylate (340 mg, 0.968 mmol, 62.8% yield) as a yellow-orange foam. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.20 (d, J = 8.80 Hz, 1 H) 8.13 (d, J = 5.66 Hz, 1 H) 7.26 (dd, J = 8.72, 1.65 Hz, 1 H) 7.23 (d, J = 1.57 Hz, 1 H) 4.48 - 4.56 (m, 1 H) 4.24 (br. s., 2 H) 3.85 - 3.91 (m, 5 H) 1.39 (s, 9 H) LCMS: [M+23] = 374, rt = 1.62 min (lipophilic method). tert-butyl 3-((2-amino-5-(methoxycarbonyl)phenyl)amino)azetidine-1- carboxylate To a solution of tert-butyl 3-((5-(methoxycarbonyl)-2-nitrophenyl)amino)azetidine-1- carboxylate (340 mg, 0.968 mmol) in ethyl acetate (25 mL) was added 10% Pd / C (34 mg, 0.097 mmol). The resulting suspension was stirred under a H 2 atmosphere (balloon) for 4 h. The contents were filtered through Celite and the solvent removed in vacuo to give tert-butyl 3-((2-amino-5-(methoxycarbonyl)phenyl)amino)azetidine- 1-carboxylate (304 mg, 0.947 mmol, 97.9% yield) as a tan solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.21 (dd, J = 8.10, 1.81 Hz, 1 H) 6.72 (d, J = 1.73 Hz, 1 H) 6.57 (d, J = 8.17 Hz, 1 H) 5.48 (s, 2 H) 5.26 (d, J = 6.13 Hz, 1 H) 4.11 - 4.23 (m, 3 H) 3.72 (s, 3 H) 3.67 (dd, J = 8.25, 4.17 Hz, 2 H) 1.39 (s, 9 H) LCMS: [M+23] = 344, rt = 1.15 min (lipophilic method). Methyl 3-(1-(tert-butoxycarbonyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylate A mixture of tert-butyl 3-((2-amino-5-(methoxycarbonyl)phenyl)amino)azetidine-1- carboxylate (304 mg, 0.947 mmol) and 1,1'-carbonyldiimidazole (276 mg, 1.70 mmol) in chloroform (8 mL) was stirred at 60 °C for 18 h. The solvent was removed under a stream of N 2 , and the residue triturated with 12 mL MeOH for 1 h, then cooled to 0 °C. The solid was collected by filtration, washed with cold MeOH and dried to give methyl 3-(1-(tert-butoxycarbonyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylate (284 mg, 0.819 mmol, 86.4% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.44 (br. s., 1 H) 7.80 (d, J = 1.10 Hz, 1 H) 7.73 (dd, J = 8.17, 1.41 Hz, 1 H) 7.12 (d, J = 8.17 Hz, 1 H) 5.24 (tt, J = 8.51, 5.56 Hz, 1 H) 4.22 - 4.40 (m, 4 H) 3.82 (s, 3 H) 1.44 (s, 9 H) LCMS: [M+23] = 370, rt = 2.28 min. Methyl 3-(azetidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-c arboxylate hydrochloride To a suspension of methyl 3-(1-(tert-butoxycarbonyl)azetidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (284 mg, 0.819 mmol) in methanol (10 mL) was added 6 N HCl (1.36 mL, 8.19 mmol). The resulting mixture was stirred at 60 °C for 6 h. The contents were allowed to cool to room temperature and stirred over the weekend, then cooled to 0 °C. The solid was collected by filtration, washed with cold MeOH and dried under vacuum to give methyl 3-(azetidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate hydrochloride (187 mg, 0.658 mmol, 80.3% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.66 (br. s., 1 H) 9.18 (br. s., 2 H) 7.82 (d, J = 1.52 Hz, 1 H) 7.73 (dd, J = 8.34, 1.52 Hz, 1 H) 7.13 (d, J = 8.08 Hz, 1 H) 5.38 - 5.48 (m, 1 H) 4.68 (dd, J = 11.50, 7.45 Hz, 2 H) 4.27 (dd, J = 11.37, 9.09 Hz, 2 H) 3.85 (s, 3 H) LCMS: [M+1] = 248, rt = 1.24 min. Example 10: 3-(1-(2,4-dichlorobenzoyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylic acid Methyl 3-(1-(2,4-dichlorobenzoyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylate A mixture of methyl 3-(azetidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride (42.0 mg, 0.148 mmol), 2,4-dichlorobenzoic acid (29.7 mg, 0.155 mmol), HBTU (58.9 mg, 0.155 mmol) and DIPEA (77.4 µL, 0.444 mmol) in chloroform (5 mL) was stirred at room temperature for 18 h. The contents were treated with water and extracted with CHCl3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N 2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 3-(1-(2,4-dichlorobenzoyl)azetidin-3-yl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylate (30.4 mg, 0.0723 mmol, 48.9% yield) as a white solid. Two amide conformers by 1H NMR -- one peak by LCMS. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.50 (s, 1 H) 7.12 - 7.92 (m, 6 H) 5.33 - 5.43 (m, 1 H) 4.25 - 4.54 (m, 4 H) 3.85 (s, 3 H) LCMS: [M+1] = 420/422/424, rt = 2.30 min. 3-(1-(2,4-dichlorobenzoyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 3-(1-(2,4-dichlorobenzoyl)azetidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (30.4 mg, 0.0723 mmol) in methanol (5 mL) was added 1 N NaOH (723 µL, 0.723 mmol). the resulting mixture was stirred at 60 °C for 40 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-(1-(2,4-dichlorobenzoyl)azetidin-3-yl)- 2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid (20.3 mg, 0.0500 mmol, 69.1% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.81 (br. s., 1 H) 11.44 (s, 1 H) 7.91 (s, 1 H) 7.77 (dd, J = 1.52, 0.76 Hz, 1 H) 7.73 (dd, J = 8.08, 1.52 Hz, 2 H) 7.55 (d, J = 1.52 Hz, 2 H) 7.11 (d, J = 8.08 Hz, 1 H) 5.32 - 5.41 (m, 1 H) 4.52 (d, J = 7.07 Hz, 2 H) 4.45 (dd, J = 9.47, 5.43 Hz, 1 H) 4.28 (t, J = 9.22 Hz, 1 H) LCMS: [M+1] = 406/408/410, rt = 1.97 min. Example 11: 3-(1-(2,4-dichlorobenzyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1H - benzo[d]imidazole-5-carboxylic acid Methyl 3-(1-(2,4-dichlorobenzyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1H - benzo[d]imidazole-5-carboxylate A mixture of methyl 3-(azetidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride (40.0 mg, 0.141 mmol), 2,4-Dichlorobenzaldehyde (25.9 mg, 0.148 mmol) and Sodium triacetoxyborohydride (89.6 mg, 0.423 mmol) in chloroform (5 mL) was stirred at room temperature for 18 h. The contents were treated with 5% Na 2 CO 3 and extracted with CHCl 3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 3-(1-(2,4-dichlorobenzyl)azetidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (28.0 mg, 0.0689 mmol, 48.9% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.41 (br. s., 1 H) 8.53 (s, 1 H) 7.74 (d, J = 8.08 Hz, 1 H) 7.64 (d, J = 2.02 Hz, 1 H) 7.61 (d, J = 8.59 Hz, 1 H) 7.46 (dd, J = 8.21, 2.15 Hz, 1 H) 7.12 (d, J = 8.08 Hz, 1 H) 5.06 (d, J = 6.57 Hz, 1 H) 3.71 - 3.89 (m, 7 H) LCMS: [M+1] = 406/408/410, rt = 1.96 min. 3-(1-(2,4-dichlorobenzyl)azetidin-3-yl)-2-oxo-2,3-dihydro-1H -benzo[d]imidazole- 5-carboxylic acid To a suspension of methyl 3-(1-(2,4-dichlorobenzyl)azetidin-3-yl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylate (28.0 mg, 0.0689 mmol) in methanol (5 mL) was added 1 N NaOH (689 µL, 0.689 mmol). the resulting mixture was stirred at 60 °C for 40 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-(1-(2,4-dichlorobenzyl)azetidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylic acid (23.5 mg, 0.0599 mmol, 86.9% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.71 (br. s., 1 H) 11.35 (s, 1 H) 8.46 (s, 1 H) 7.71 (dd, J = 8.08, 1.52 Hz, 1 H) 7.64 (d, J = 8.34 Hz, 1 H) 7.61 (d, J = 2.27 Hz, 1 H) 7.43 (dd, J = 8.34, 2.27 Hz, 1 H) 7.09 (d, J = 8.34 Hz, 1 H) 4.99 - 5.08 (m, 1 H) 3.87 (s, 2 H) 3.72 - 3.81 (m, 4 H) LCMS: [M+1] = 392/394/396, rt = 1.79 min. Intermediate C: Methyl (S)-2-oxo-3-(pyrrolidin-3-yl)-2,3-dihydro - benzo[d]imidazole-5-carboxylate hydrochloride tert-butyl (S)-3-((5-(methoxycarbonyl)-2-nitrophenyl)amino)pyrrolidine- 1- carboxylate A mixture of methyl 3-fluoro-4-nitrobenzoate (306 mg, 1.54 mmol), tert-butyl (S)-3- aminopyrrolidine-1-carboxylate (343 mg, 1.84 mmol) and cesium carbonate (601 mg, 1.84 mmol) in MeCN (5 mL) was stirred at 30 °C for 24 h, then at 60 °C for 12 h. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO4, filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-50% EtOAc/heptane, 20 g silica gel cartridge) to give tert-butyl (S)-3-((5-(methoxycarbonyl)-2- nitrophenyl)amino)pyrrolidine-1-carboxylate (400 mg, 1.095 mmol, 71.2% yield) as a yellow-orange foam. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.19 (d, J = 8.80 Hz, 1 H) 7.89 (br. s., 1 H) 7.57 (s, 1 H) 7.22 (dd, J = 8.88, 1.49 Hz, 1 H) 4.37 - 4.49 (m, 1 H) 3.90 (s, 3 H) 3.68 (dd, J = 9.98, 6.21 Hz, 1 H) 3.35 - 3.45 (m, 2 H) 3.26 (dd, J = 10.93, 4.48 Hz, 1 H) 2.25 (dd, J = 12.65, 6.37 Hz, 1 H) 1.93 - 2.07 (m, 1 H) 1.41 (br. s., 9 H) LCMS: [M+23] = 388, rt = 1.70 min (lipophilic method). tert-butyl (S)-3-((2-amino-5-(methoxycarbonyl)phenyl)amino)pyrrolidine- 1- carboxylate To a solution of tert-butyl (S)-3-((5-(methoxycarbonyl)-2- nitrophenyl)amino)pyrrolidine-1-carboxylate (400 mg, 1.09 mmol) in ethyl acetate (25 mL) was added 10% Pd / C (40 mg, 0.109 mmol). The resulting suspension was stirred under a H 2 atmosphere (balloon) for 16 h, filtered through Celite and the solvent removed in vacuo to give tert-butyl (S)-3-((2-amino-5- (methoxycarbonyl)phenyl)amino)pyrrolidine-1-carboxylate (378 mg, 1.13 mmol, 103% yield) as a tan foam. 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.18 (dd, J = 8.10, 1.81 Hz, 1 H) 6.99 (s, 1 H) 6.55 (d, J = 8.17 Hz, 1 H) 5.48 - 5.52 (m, 2 H) 4.71 (d, J = 5.66 Hz, 1 H) 3.94 - 4.04 (m, 1 H) 3.73 (s, 3 H) 3.54 - 3.61 (m, 1 H) 3.34 - 3.45 (m, 2 H) 3.12 - 3.20 (m, 1 H) 2.07 - 2.19 (m, 1 H) 1.85 (td, J = 12.18, 5.50 Hz, 1 H) 1.40 (d, J = 6.29 Hz, 9 H) LCMS: [M+1] = 336, rt = 1.21 min (lipophilic method). Methyl (S)-3-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-oxo-2,3-dih ydro-1H- benzo[d]imidazole-5-carboxylate A mixture of tert-butyl (S)-3-((2-amino-5- (methoxycarbonyl)phenyl)amino)pyrrolidine-1-carboxylate (378 mg, 1.13 mmol) and 1,1'-carbonyldiimidazole (366 mg, 2.26 mmol) in chloroform (10 mL) was stirred at 60 °C for 4 h. The solvent was removed under a stream of N 2 , and the residue triturated with MeOH/H 2 O (1:1) for 65 h. The solid was collected by filtration, washed with MeOH/water (1:3) and dried to give methyl (S)-3-(1-(tert- butoxycarbonyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d ]imidazole-5- carboxylate (317 mg, 0.877 mmol, 77.8% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.42 (s, 1 H) 7.68 - 7.74 (m, 2 H) 7.10 (d, J = 8.34 Hz, 1 H) 5.07 (br. s., 1 H) 3.83 (s, 3 H) 3.52 - 3.70 (m, 3 H) 2.44 (d, J = 9.60 Hz, 2 H) 2.15 (br. s., 1 H) 1.43 (d, J = 11.87 Hz, 9 H) LCMS: [M+23] = 384, rt = 2.28 min. Methyl (S)-2-oxo-3-(pyrrolidin-3-yl)-2,3-dihydro-1H-benzo[d]imidazo le-5- carboxylate hydrochloride To a suspension of methyl (S)-3-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (317 mg, 0.877 mmol) in methanol (10 mL) was added 6 N HCl (1.46 mL, 8.77 mmol). The resulting mixture was stirred at 60 °C for 90 min. The solvent was removed in vacuo to give methyl (S)-2-oxo-3- (pyrrolidin-3-yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxy late hydrochloride (262 mg, 0.879 mmol, 100% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.60 (s, 1 H) 9.50 (br. s., 1 H) 9.07 (br. s., 1 H) 7.82 (d, J = 1.26 Hz, 1 H) 7.73 (dd, J = 8.34, 1.52 Hz, 1 H) 7.13 (d, J = 8.34 Hz, 1 H) 5.18 (dt, J = 14.34, 7.11 Hz, 1 H) 3.85 (s, 3 H) 3.63 - 3.73 (m, 1 H) 3.45 - 3.60 (m, 2 H) 3.29 (dt, J = 11.37, 5.94 Hz, 1 H) 2.35 (q, J = 7.33 Hz, 2 H) LCMS: [M+1] = 262, rt = 1.36 min. Example 12: (S)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dih ydro- 1H-benzo[d]imidazole-5-carboxylic acid Methyl (S)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dih ydro-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl (S)-2-oxo-3-(pyrrolidin-3-yl)-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate hydrochloride (53.0 mg, 0.178 mmol), 2,4- dichlorobenzoic acid (37.4 mg, 0.196 mmol), HBTU (74.3 mg, 0.196 mmol) and DIPEA (124 µL, 0.712 mmol) in chloroform (5 mL) was stirred at room temperature for 21 h. The contents were treated with water and extracted with CHCl3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl (S)-3-(1-(2,4- dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[ d]imidazole-5- carboxylate (65.0 mg, 0.150 mmol, 84.1% yield) as a beige foam. Two amide conformers seen by 1 H NMR — one peak by LCMS. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.37 - 11.48 (m, 1 H) 7.45 - 7.81 (m, 5 H) 7.10 (dd, J = 18.44, 8.34 Hz, 1 H) 5.07 - 5.24 (m, 1 H) 3.86 - 4.00 (m, 1 H) 3.85 (d, J = 2.78 Hz, 3 H) 3.45 - 3.72 (m, 3 H) 2.34 (br. s., 2 H) LCMS: [M+1] = 434/436/438, rt = 2.32 min. (S)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dih ydro-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl (S)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (65.0 mg, 0.150 mmol) in methanol (5 mL) was added 1 N NaOH (1.50 mL, 1.50 mmol). The resulting mixture was stirred at 60 °C for 3 h, then at 40 °C for 65 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give (S)-3-(1-(2,4- dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[ d]imidazole-5- carboxylic acid (38.7 mg, 0.0921 mmol, 51.7% yield) as an off-white solid. Two amide conformers seen by 1 H NMR — one peak by LCMS. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.78 (br. s., 1 H) 11.31 - 11.42 (m, 1 H) 7.46 - 7.80 (m, 5 H) 7.07 (dd, J = 18.70, 8.34 Hz, 1 H) 5.05 - 5.24 (m, 1 H) 3.38 - 4.00 (m, 4 H) 2.15 - 2.46 (m, 2 H) LCMS: [M+1] = 420/422/424, rt = 2.00 min. Example 13: (S)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3-dihy dro-1H- benzo[d]imidazole-5-carboxylic acid Methyl (S)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3-dihy dro-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl (S)-2-oxo-3-(pyrrolidin-3-yl)-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate hydrochloride (53.0 mg, 0.178 mmol), 2,4- dichlorobenzaldehyde (34.3 mg, 0.196 mmol) and sodium triacetoxyborohydride (113 mg, 0.534 mmol) in chloroform (5 mL) was stirred at room temperature for 45 h. The contents were treated with 5% Na 2 CO 3 and extracted with CHCl 3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl (S)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2- oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (48.6 mg, 0.116 mmol, 65.0% yield) as a white foam. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.34 (br. s., 1 H) 8.32 (d, J = 1.52 Hz, 1 H) 7.78 (d, J = 8.34 Hz, 1 H) 7.71 (dd, J = 8.21, 1.64 Hz, 1 H) 7.62 (d, J = 2.27 Hz, 1 H) 7.41 (dd, J = 8.34, 2.27 Hz, 1 H) 7.08 (d, J = 8.34 Hz, 1 H) 5.05 - 5.15 (m, 1 H) 3.85 (s, 3 H) 3.78 (d, J = 3.03 Hz, 2 H) 3.15 (t, J = 7.96 Hz, 1 H) 3.00 (dd, J = 10.36, 3.03 Hz, 1 H) 2.70 (t, J = 9.85 Hz, 1 H) 2.32 - 2.42 (m, 1 H) 2.17 - 2.28 (m, 1 H) 1.95 - 2.07 (m, 1 H) LCMS: [M+1] = 420/422/424, rt = 2.00 min. (S)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3-dihy dro-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl (S)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (48.6mg, 0.1200mmol) in Methanol (5mL) was added 1 N NaOH (1.16mL, 1.16mmol). The resulting mixture was stirred at 60 ºC for 21 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give (S)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3- yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid hydrochloride (32.9 mg, 0.0743 mmol, 64.3% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.82 (br. s., 1 H) 11.67 (s, 1 H) 11.52 (br. s., 1 H) 11.03 (br. s., 1 H) 10.21 (br. s., 1 H) 7.57 - 7.92 (m, 5 H) 7.07 - 7.15 (m, 1 H) 5.10 - 5.48 (m, 2 H) 4.62 - 4.79 (m, 2 H) 3.57 - 3.98 (m, 4 H) LCMS: [M+1] = 406/408/410, rt = 1.83 min. Intermediate D: Methyl (R)-2-oxo-3-(pyrrolidin-3-yl)-2,3-dihydro - benzo[d]imidazole-5-carboxylate hydrochloride tert-butyl (R)-3-((5-(methoxycarbonyl)-2-nitrophenyl)amino)pyrrolidine- 1- carboxylate A mixture of methyl 3-fluoro-4-nitrobenzoate (298 mg, 1.50 mmol), tert-butyl (R)-3- aminopyrrolidine-1-carboxylate (334 mg, 1.80 mmol) and cesium carbonate (585 mg, 1.80 mmol) in MeCN (5 mL) was stirred at 50 °C for 17 h. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO 4 , filtered and the solvent removed in vacuo to give a residue which was purified by automated normal- phase chromatography (0-50% EtOAc/heptane, 20 g silica gel cartridge) to give tert- butyl (R)-3-((5-(methoxycarbonyl)-2-nitrophenyl)amino)pyrrolidine- 1-carboxylate (340 mg, 0.931 mmol, 62.2% yield) as a yellow-orange gum. 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.20 (d, J = 8.80 Hz, 1 H) 7.89 (br. s., 1 H) 7.58 (s, 1 H) 7.22 (dd, J = 8.80, 1.57 Hz, 1 H) 4.43 (d, J = 16.66 Hz, 1 H) 3.90 (s, 3 H) 3.64 - 3.71 (m, 1 H) 3.35 - 3.45 (m, 2 H) 3.26 (dd, J = 11.00, 4.40 Hz, 1 H) 2.19 - 2.30 (m, 1 H) 1.94 - 2.08 (m, 1 H) 1.41 (br. s., 9 H) LCMS: [M+23] = 388, rt = 1.70 min (lipophilic method). tert-butyl (R)-3-((2-amino-5-(methoxycarbonyl)phenyl)amino)pyrrolidine- 1- carboxylate To a solution of tert-butyl (R)-3-((5-(methoxycarbonyl)-2- nitrophenyl)amino)pyrrolidine-1-carboxylate (340 mg, 0.931 mmol) in ethyl acetate (25 mL) was added 10% Pd / C (35.0 mg, 0.093 mmol). The resulting suspension was stirred under a H 2 atmosphere (balloon) for 18 h. The contents were filtered through Celite and the solvent removed in vacuo to give tert-butyl (R)-3-((2-amino-5- (methoxycarbonyl)phenyl)amino)pyrrolidine-1-carboxylate (332 mg, 0.990 mmol, 106% yield) as a tan foam. This material was used without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 7.18 (dd, J = 8.17, 1.73 Hz, 1 H) 6.99 (s, 1 H) 6.55 (d, J = 8.17 Hz, 1 H) 5.50 (s, 2 H) 4.71 (d, J = 5.66 Hz, 1 H) 3.94 - 4.05 (m, 1 H) 3.73 (s, 3 H) 3.53 - 3.61 (m, 1 H) 3.34 - 3.45 (m, 2 H) 3.16 (t, J = 11.71 Hz, 1 H) 2.08 - 2.19 (m, 1 H) 1.85 (td, J = 12.42, 5.19 Hz, 1 H) 1.40 (d, J = 5.97 Hz, 9 H) LCMS: [M+23] = 358, rt = 1.21 min (lipophilic method). Methyl (R)-3-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-oxo-2,3-dih ydro-1H- benzo[d]imidazole-5-carboxylate A mixture of tert-butyl (R)-3-((2-amino-5- (methoxycarbonyl)phenyl)amino)pyrrolidine-1-carboxylate (332 mg, 0.990 mmol) and 1,1'-carbonyldiimidazole (321 mg, 1.98mmol) in chloroform (10 mL) was stirred at 60 °C for 4 h. The solvent was removed under a stream of N2, and the residue triturated with MeOH/H 2 O (1:1) for 65 h. The solid was collected by filtration, washed with MeOH/water (1:3) and dried to give methyl (R)-3-(1-(tert- butoxycarbonyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d ]imidazole-5- carboxylate (284 mg, 0.787 mmol, 79.5% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.42 (br. s., 1 H) 7.67 - 7.75 (m, 2 H) 7.10 (d, J = 8.34 Hz, 1 H) 5.06 (br. s., 1 H) 3.84 (s, 3 H) 3.51 - 3.71 (m, 3 H) 2.34 (br. s., 2 H) 2.16 (br. s., 1 H) 1.43 (d, J = 11.12 Hz, 9 H) LCMS: [M+23] = 384, rt = 2.28 min. Methyl (R)-2-oxo-3-(pyrrolidin-3-yl)-2,3-dihydro-1H-benzo[d]imidazo le-5- carboxylate hydrochloride To a suspension of methyl (R)-3-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (284 mg, 0.7987 mmol) in methanol (10 mL) was added 6 N HCl (1.31 mL, 7.86 mmol). The resulting mixture was stirred at 60 °C for 90 min. The solvent was removed in vacuo to give methyl (R)-2-oxo-3- (pyrrolidin-3-yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxy late hydrochloride (229 mg, 0.768 mmol, 97.6% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.61 (s, 1 H) 9.53 (br. s., 1 H) 9.09 (br. s., 1 H) 7.83 (s, 1 H) 7.74 (dd, J = 8.34, 1.52 Hz, 1 H) 7.13 (d, J = 8.08 Hz, 1 H) 5.12 - 5.24 (m, 1 H) 3.86 (s, 3 H) 3.67 (br. s., 1 H) 3.52 (br. s., 2 H) 3.29 (br. s., 1 H) 2.35 (q, J = 7.24 Hz, 2 H) LCMS: [M+1] = 262, rt = 1.36 min. Example 14: (R)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dih ydro- 1H-benzo[d]imidazole-5-carboxylic acid Methyl (R)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dih ydro-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl (R)-2-oxo-3-(pyrrolidin-3-yl)-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate hydrochloride (53.0 mg, 0.178 mmol), 2,4- dichlorobenzoic acid (37.4 mg, 0.196 mmol), HBTU (74.3 mg, 0.196 mmol) and DIPEA (124 µL, 0.712 mmol) in chloroform (5 mL) was stirred at room temperature for 21 h. The contents were treated with water and extracted with CHCl 3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N 2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl (R)-3-(1-(2,4- dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[ d]imidazole-5- carboxylate (60.0 mg, 0.138 mmol, 77.6% yield) as a white foam. Two amide conformers seen by 1H NMR — one peak by LCMS. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.37 - 11.47 (m, 1 H) 7.45 - 7.81 (m, 5 H) 7.10 (dd, J = 18.70, 8.34 Hz, 1 H) 5.06 - 5.24 (m, 1 H) 3.87 - 4.01 (m, 1 H) 3.85 (d, J = 2.78 Hz, 3 H) 3.38 - 3.72 (m, 3 H) 2.16 - 2.35 (m, 2 H) LCMS: [M+1] = 434/436/468, rt = 2.32 min. (R)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dih ydro-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl (R)-3-(1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (60.0 mg, 0.138 mmol) in methanol (5 mL) was added 1 N NaOH (1.38 mL, 1.38 mmol). The resulting mixture was stirred at 60 °C for 3 h, then at 40 °C for 65 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give (R)-3-(1-(2,4- dichlorobenzoyl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[ d]imidazole-5- carboxylic acid (39.6 mg, 0.0942 mmol, 68.2% yield) as an off-white solid. Two amide conformers by 1H NMR — one peak by LCMS. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.77 (br. s., 1 H) 11.31 - 11.41 (m, 1 H) 7.46 - 7.80 (m, 5 H) 7.07 (dd, J = 18.57, 8.21 Hz, 1 H) 5.05 - 5.24 (m, 1 H) 3.39 - 4.01 (m, 4 H) 2.14 - 2.43 (m, 2 H) LCMS: [M+1] = 420/422/424, rt = 2.00 min. Example 15: (R)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3-dihy dro - benzo[d]imidazole-5-carboxylic acid Methyl (R)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3-dihy dro-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl (R)-2-oxo-3-(pyrrolidin-3-yl)-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate hydrochloride (53.0 mg, 0.178 mmol), 2,4- dichlorobenzaldehyde (34.3 mg, 0.196 mmol) and sodium triacetoxyborohydride (113 mg, 0.534 mmol) in chloroform (5 mL) was stirred at room temperature for 45 h. The contents were treated with 5% Na2CO3 and extracted with CHCl3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N 2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl (R)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2- oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (46.0 mg, 0.109 mmol, 61.5% yield) as a white foam. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.34 (br. s., 1 H) 8.32 (d, J = 1.52 Hz, 1 H) 7.78 (d, J = 8.34 Hz, 1 H) 7.71 (dd, J = 8.34, 1.52 Hz, 1 H) 7.62 (d, J = 2.27 Hz, 1 H) 7.41 (dd, J = 8.34, 2.27 Hz, 1 H) 7.08 (d, J = 8.34 Hz, 1 H) 5.05 - 5.15 (m, 1 H) 3.85 (s, 3 H) 3.78 (d, J = 3.03 Hz, 2 H) 3.15 (t, J = 7.96 Hz, 1 H) 3.00 (dd, J = 10.36, 3.03 Hz, 1 H) 2.70 (t, J = 9.73 Hz, 1 H) 2.32 - 2.42 (m, 1 H) 2.17 - 2.28 (m, 1 H) 1.94 - 2.07 (m, 1 H) LCMS: [M+1] = 420/422/424, rt = 1.99 min. (R)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3-dihy dro-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl (R)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (46.0 mg, 0.109 mmol) in methanol (5 mL) was added 1 N NaOH (1.09 mL, 1.09 mmol). The resulting mixture was stirred at 60 °C for 21 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give (R)-3-(1-(2,4-dichlorobenzyl)pyrrolidin-3- yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid hydrochloride (27.2 mg, 0.0614 mmol, 56.1% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.81 (br. s., 1 H) 11.67 (s, 1 H) 11.52 (br. s., 1 H) 10.92 (br. s., 1 H) 10.17 (br. s., 1 H) 7.58 - 7.90 (m, 5 H) 7.07 - 7.15 (m, 1 H) 5.43 (br. s., 1 H) 5.16 (br. s., 1 H) 4.73 (br. s., 1 H) 4.65 (br. s., 1 H) 3.57 - 3.98 (m, 4 H) LCMS: [M+1] = 406/408/410, rt = 1.82 min. Intermediate E: Methyl 2-oxo-1-(piperidin-4-yl)-2,3-dihydro- - benzo[d]imidazole-5-carboxylate hydrochloride tert-butyl 4-((4-(methoxycarbonyl)-2-nitrophenyl)amino)piperidine-1- carboxylate A mixture of methyl 4-chloro-3-nitrobenzoate (325 mg, 1.51 mmol), tert-butyl 4- aminopiperidine-1-carboxylate (362 mg, 1.81 mmol) and cesium carbonate (589 mg, 1.81 mmol) in MeCN (8 mL) was stirred at room temperature for 17 h, then at 50 °C for 26 h, then at 30 °C for 3 days. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO 4 , filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0- 100% EtOAc/heptane, 20 g silica gel cartridge) to give tert-butyl 4-((4- (methoxycarbonyl)-2-nitrophenyl)amino)piperidine-1-carboxyla te (340 mg, 0.896 mmol, 59.4% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.63 (d, J = 2.04 Hz, 1 H) 8.24 (d, J = 8.02 Hz, 1 H) 7.98 (dd, J = 9.12, 2.04 Hz, 1 H) 7.29 (d, J = 9.27 Hz, 1 H) 3.92 (dd, J = 7.62, 3.38 Hz, 3 H) 3.83 (s, 3 H) 2.96 (br. s., 2 H) 1.94 (d, J = 10.22 Hz, 2 H) 1.51 (q, J = 10.53 Hz, 2 H) 1.41 (s, 9 H) LCMS: [M+23] = 402, rt = 1.80 min (lipophilic method). tert-butyl 4-((2-amino-4-(methoxycarbonyl)phenyl)amino)piperidine-1- carboxylate To a solution of tert-butyl 4-((4-(methoxycarbonyl)-2-nitrophenyl)amino)piperidine- 1-carboxylate (340 mg, 0.896 mmol) in ethyl acetate (25 mL) was added 10% Pd / C (35 mg, 0.090 mmol). The resulting mixture was stirred under atmospheric H 2 (balloon) for 6 days (for convenience). The contents were filtered through Celite and the solvent removed in vacuo to give tert-butyl 4-((2-amino-4- (methoxycarbonyl)phenyl)amino)piperidine-1-carboxylate (325 mg,0.929 mmol, 103% yield) as a greenish-gray foam. This material was sued without further purification. 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.16 - 7.20 (m, 2 H) 6.53 (d, J = 8.17 Hz, 1 H) 4.98 (d, J = 7.55 Hz, 1 H) 4.77 (br. s., 2 H) 3.92 (d, J = 11.16 Hz, 2 H) 3.72 (s, 3 H) 3.49 - 3.58 (m, 1 H) 2.91 (br. s., 2 H) 1.87 - 1.96 (m, 2 H) 1.41 (s, 9 H) 1.23 - 1.34 (m, 2 H) LCMS: [M+1] = 350, rt = 1.14 min (lipophilic method). Methyl 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylate A mixture of tert-butyl 4-((2-amino-4-(methoxycarbonyl)phenyl)amino)piperidine-1- carboxylate (310 mg, 0.887 mmol) and 1,1'-carbonyldiimidazole (216 mg, 1.33 mmol) in chloroform (10 mL) was stirred at 60 °C for 21 h. The reaction mixture was reduced in volume with a stream of N2 and purified by automated normal-phase chromatography (0-100% EtOAc/heptane, 20 g silica gel cartridge) to give methyl 1- (1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H -benzo[d]imidazole-5- carboxylate (255 mg, 0.678 mmol, 76.5% yield) as a gray foam. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.17 (s, 1 H) 7.68 (dd, J = 8.33, 1.57 Hz, 1 H) 7.51 (d, J = 1.57 Hz, 1 H) 7.35 (d, J = 8.33 Hz, 1 H) 4.33 - 4.42 (m, 1 H) 4.10 (br. s., 2 H) 3.83 (s, 3 H) 2.88 (br. s., 2 H) 2.19 (qd, J = 12.50, 4.48 Hz, 2 H) 1.71 (d, J = 10.38 Hz, 2 H) 1.44 (s, 9 H) LCMS: [M+23] = 398, rt = 1.26 min (lipophilic method). Methyl 2-oxo-1-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride To a suspension of methyl 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (255 mg, 0.678 mmol) in methanol (5 mL) was added 6 N HCl (1.13 mL, 6.77 mmol). The resulting mixture was stirred at 60 °C for 4 h. The solvent was removed in vacuo to give methyl 2-oxo-1-(piperidin-4- yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate hydrochloride (191 mg, 0.614 mmol, 90.7% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.26 (s, 1 H) 8.77 - 8.93 (m, 2 H) 7.71 (dd, J = 8.41, 1.65 Hz, 1 H) 7.54 (d, J = 1.41 Hz, 1 H) 7.52 (d, J = 8.49 Hz, 1 H) 4.53 - 4.62 (m, 1 H) 3.84 (s, 3 H) 3.42 (d, J = 12.42 Hz, 2 H) 3.09 (q, J = 11.69 Hz, 2 H) 2.55 - 2.66 (m, 2 H) 1.88 (d, J = 12.26 Hz, 2 H) LCMS: [M+1] = 276, rt = 1.41 min Example 16: 1-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylic acid Methyl 1-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylate A mixture of methyl 2-oxo-1-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride (50.0 mg, 0.160 mmol), 2,4-dichlorobenzoic acid (33.7 mg, 0.176 mmol), HBTU (66.9 mg, 0.176 mmol) and DIPEA (112 µL, 0.642 mmol) in chloroform (5 mL) was stirred at room temperature for 18 h. The contents were treated with water and extracted with CHCl3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 1-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (49.3 mg, 0.110 mmol, 68.6% yield) as a white foam. Two amide conformers by 1 H NMR — one peak by LCMS. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.23 (d, J = 8.34 Hz, 1 H) 7.25 - 7.80 (m, 6 H) 4.47 - 4.73 (m, 2 H) 3.84 (s, 3 H) 3.24 (d, J = 16.67 Hz, 1 H) 2.89 - 3.00 (m, 1 H) 2.08 - 2.40 (m, 2 H) 1.61 - 1.91 (m, 2 H) LCMS: [M+1] = 448/450/452, rt = 2.41 min. 1-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 1-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (49.3 mg, 0.110 mmol) in methanol (5 mL) was added 1 N NaOH (1.10 mL, 1.10 mmol). The resulting mixture was stirred at 60 °C for 3 h, then at 40 °C for 65 h, then at 60 °C for 2 h. The solvent was removed under a stream of N2, and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1-(1-(2,4-dichlorobenzoyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H- benzo[d]imidazole-5-carboxylic acid (33.5 mg, 0.0771 mmol, 70.1% yield) as a white solid. Two amide conformers seen by 1 H NMR — one peak by LCMS. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.71 (br. s., 1 H) 11.17 (d, J = 7.58 Hz, 1 H) 7.21 - 7.80 (m, 6 H) 4.69 (d, J = 11.87 Hz, 1 H) 4.46 - 4.59 (m, 1 H) 3.17 - 3.41 (m, 2 H) 2.90 - 3.01 (m, 1 H) 2.11 - 2.39 (m, 2 H) 1.61 - 1.93 (m, 2 H) LCMS: [M+1] = 434/436/438, rt = 2.13 min. Example 17: 1-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylic acid Methyl 1-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylate A mixture of methyl 2-oxo-1-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazole-5- carboxylate hydrochloride (50.0 mg, 0.160 mmol), 2,4-dichlorobenzaldehyde (30.9 mg, 0.176 mmol) and sodium triacetoxyborohydride (119 mg, 0.561 mmol) in chloroform (5 mL) was stirred at room temperature for 41 h. The contents were treated with water and extracted with CHCl3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N 2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 1-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-carboxylate (36.6 mg, 0.0843 mmol, 52.5% yield) as a white foam. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.20 (s, 1 H) 7.70 (dd, J = 8.34, 1.77 Hz, 1 H) 7.58 - 7.63 (m, 2 H) 7.51 (d, J = 1.52 Hz, 1 H) 7.46 (dd, J = 8.34, 2.02 Hz, 1 H) 7.38 (d, J = 8.34 Hz, 1 H) 4.16 - 4.27 (m, 1 H) 3.83 (s, 3 H) 3.61 (s, 2 H) 2.96 (d, J = 10.86 Hz, 2 H) 2.31 - 2.41 (m, 2 H) 2.19 - 2.28 (m, 2 H) 1.69 (d, J = 11.62 Hz, 2 H) LCMS: [M+1] = 434/436/438, rt = 2.00 min. 1-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 1-(1-(2,4-dichlorobenzyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylate (36.6 mg, 0.0843 mmol) in methanol (5 mL) was added 1 N NaOH (843 µL, 0.843 mmol). The resulting mixture was stirred at 60 °C for 21 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 1-(1-(2,4-dichlorobenzyl)piperidin-4-yl)- 2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid (25.9 mg, 0.0616 mmol, 73.1% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.69 (br. s., 1 H) 11.14 (s, 1 H) 7.68 (dd, J = 8.34, 1.77 Hz, 1 H) 7.59 - 7.63 (m, 2 H) 7.50 (d, J = 1.77 Hz, 1 H) 7.46 (dd, J = 8.21, 2.15 Hz, 1 H) 7.34 (d, J = 8.59 Hz, 1 H) 4.21 (t, J = 12.13 Hz, 1 H) 3.61 (s, 2 H) 2.96 (d, J = 11.12 Hz, 2 H) 2.32 - 2.44 (m, 2 H) 2.18 - 2.28 (m, 2 H) 1.68 (d, J = 11.37 Hz, 2 H) LCMS: [M+1] = 420/422/424, rt = 1.83 min. Intermediate F: Methyl 2-oxo-3-(pyrrolidin-3-ylmethyl)-2,3-dihydro - benzo[d]imidazole-5-carboxylate hydrochloride tert-butyl 3-(((5-(methoxycarbonyl)-2-nitrophenyl)amino)methyl)pyrrolid ine-1- carboxylate A mixture of methyl 3-fluoro-4-nitrobenzoate (300 mg, 1.51 mmol), tert-butyl 3- (aminomethyl)pyrrolidine-1-carboxylate (362 mg, 1.81 mmol) and cesium carbonate (589 mg, 1.81 mmol) in MeCN (5 mL) was stirred at 70 °C for 2 h, then at 40 °C for 65 h. The contents were taken up in EtOAc, washed with water (3x), brine (1x), dried over MgSO4, filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-50% EtOAc/heptane, 20 g silica gel cartridge) to give tert-butyl 3-(((5-(methoxycarbonyl)-2- nitrophenyl)amino)methyl)pyrrolidine-1-carboxylate (530 mg, 1.40 mmol, 92.7% yield) as a tacky orange solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.16 - 8.22 (m, 2 H) 7.55 (d, J = 1.52 Hz, 1 H) 7.17 (dd, J = 8.84, 1.52 Hz, 1 H) 3.89 (s, 3 H) 3.37 - 3.51 (m, 4 H) 3.17 - 3.29 (m, 1 H) 3.01 - 3.10 (m, 1 H) 2.53 - 2.62 (m, 1 H) 1.91 - 2.04 (m, 1 H) 1.67 (td, J = 13.26, 7.83 Hz, 1 H) 1.39 (s, 9 H) LCMS: [M+23] = 402, rt = 1.72 min (lipophilic method). tert-butyl 3-(((2-amino-5-(methoxycarbonyl)phenyl)amino)methyl)pyrrolid ine-1- carboxylate To a solution of tert-butyl 3-(((5-(methoxycarbonyl)-2- nitrophenyl)amino)methyl)pyrrolidine-1-carboxylate (530 mg, 1.40 mmol) in ethyl acetate (25 mL) was added 10% Pd / C (60 mg, 0.14 mmol). The resulting suspension was stirred under a H 2 atmosphere (balloon) for 6 days (for convenience). The contents were filtered through Celite and the solvent removed in vacuo to give tert- butyl 3-(((2-amino-5-(methoxycarbonyl)phenyl)amino)methyl)pyrrolid ine-1- carboxylate (502 mg, 1.44 mmol, 102% yield) as a tan foam. 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.16 (dd, J = 8.08, 2.02 Hz, 1 H) 6.96 (d, J = 2.02 Hz, 1 H) 6.54 (d, J = 8.08 Hz, 1 H) 5.51 (s, 2 H) 4.63 (br. s., 1 H) 3.73 (s, 3 H) 3.47 - 3.56 (m, 1 H) 3.32 - 3.41 (m, 1 H) 3.17 - 3.29 (m, 1 H) 2.98 - 3.07 (m, 3 H) 2.39 - 2.48 (m, 1 H) 2.04 (br. s., 1 H) 1.67 (td, J = 13.07, 8.46 Hz, 1 H) 1.40 (s, 9 H) LCMS: [M+23] = 372, rt = 1.17 min (lipophilic method). Methyl 3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3 -dihydro-1H- benzo[d]imidazole-5-carboxylate A mixture of tert-butyl 3-(((2-amino-5- (methoxycarbonyl)phenyl)amino)methyl)pyrrolidine-1-carboxyla te (502 mg, 1.44 mmol) and 1,1'-carbonyldiimidazole (419 mg, 2.59 mmol) in chloroform (10 mL) was stirred at 60 °C for 20 h. After cooling, the solvent volume was reduced with a stream of N 2 . The residue was triturated with water/MeOH (2:1) for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give methyl 3- ((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3-d ihydro-1H- benzo[d]imidazole-5-carboxylate (447 mg, 1.19 mmol, 82.9% yield) as a beige solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.37 (br. s., 1 H) 7.75 (d, J = 1.26 Hz, 1 H) 7.70 (dd, J = 8.21, 1.64 Hz, 1 H) 7.10 (d, J = 8.08 Hz, 1 H) 3.89 (d, J = 4.80 Hz, 2 H) 3.84 (s, 3 H) 3.28 - 3.35 (m, 2 H) 3.14 - 3.25 (m, 1 H) 2.98 - 3.10 (m, 1 H) 2.57 - 2.67 (m, 1 H) 1.80 - 1.91 (m, 1 H) 1.57 - 1.69 (m, 1 H) 1.38 (d, J = 5.81 Hz, 9 H) LCMS: [M-100+1] = 276, rt = 2.27 min (lipophilic method). Methyl 2-oxo-3-(pyrrolidin-3-ylmethyl)-2,3-dihydro-1H-benzo[d]imida zole-5- carboxylate hydrochloride To a suspension of methyl 3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-2-oxo- 2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (447 mg, 1.19 mmol) in methanol (10 mL) was added 6 N HCl (1.98 mL, 11.9 mmol). The resulting mixture was stirred at 60 °C for 1 h, then allowed to cool to room temperature with stirring overnight. The solvent volume was reduced with a stream of N 2 , then removed under vacuum to give methyl 2-oxo-3-(pyrrolidin-3-ylmethyl)-2,3-dihydro-1H-benzo[d]imida zole-5- carboxylate hydrochloride (362 mg, 1.16 mmol, 97.5% yield) as a tan foam. 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.45 (s, 1 H) 9.09 (br. s., 2 H) 7.81 (d, J = 1.26 Hz, 1 H) 7.72 (dd, J = 8.34, 1.52 Hz, 1 H) 7.11 (d, J = 8.08 Hz, 1 H) 3.97 (dd, J = 7.20, 2.15 Hz, 2 H) 3.85 (s, 3 H) 3.20 - 3.33 (m, 2 H) 3.03 - 3.15 (m, 1 H) 2.89 - 3.00 (m, 1 H) 2.73 (dt, J = 15.28, 7.52 Hz, 1 H) 1.92 - 2.03 (m, 1 H) 1.67 (dq, J = 12.88, 8.42 Hz, 1 H) LCMS: [M+1] = 276, rt = 1.36 min. Example 18: 3-((1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-carboxylic acid Methyl 3-((1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3- dihydro-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl 2-oxo-3-(pyrrolidin-3-ylmethyl)-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate hydrochloride (50.0 mg, 0.160 mmol), 2,4- dichlorobenzaldehyde (35.1 mg, 0.201 mmol) and sodium triacetoxyborohydride (102 mg, 0.481 mmol) in chloroform (5 mL) was stirred at room temperature for 18 h. The contents were treated with 5% Na2CO3 and extracted with CHCl3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 3-((1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)methyl)- 2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (44.6 mg, 0.103 mmol, 64.0% yield) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.33 (br. s., 1 H) 7.67 - 7.71 (m, 2 H) 7.57 (d, J = 2.27 Hz, 1 H) 7.54 (d, J = 8.34 Hz, 1 H) 7.39 (dd, J = 8.21, 2.15 Hz, 1 H) 7.08 (d, J = 8.84 Hz, 1 H) 3.78 - 3.90 (m, 4 H) 3.58 - 3.70 (m, 2 H) 2.61 - 2.71 (m, 2 H) 2.40 - 2.48 (m, 2 H) 1.81 - 1.93 (m, 1 H) 1.55 (td, J = 13.20, 6.44 Hz, 1 H) LCMS: [M+1] = 434/436/438, rt = 1.95 min. 3-((1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3- dihydro-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 3-((1-(2,4-dichlorobenzyl)pyrrolidin-3-yl)methyl)-2-oxo- 2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (44.6 mg, 0.103 mmol) in methanol (5 mL) was added 1 N NaOH (1.03 mL, 1.03 mmol). The resulting mixture was stirred at 60 °C for 46 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-((1-(2,4- dichlorobenzyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5- carboxylic acid hydrochloride (33.7 mg, 0.0738 mmol, 71.9% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.76 (br. s., 1 H) 11.35 (s, 1 H) 10.37 (br. s., 1 H) 7.75 - 7.83 (m, 3 H) 7.70 (d, J = 8.08 Hz, 1 H) 7.55 - 7.63 (m, 1 H) 7.08 (d, J = 8.08 Hz, 1 H) 4.48 - 4.56 (m, 2 H) 3.93 - 4.07 (m, 2 H) 3.44 - 3.61 (m, 2 H) 2.97 - 3.14 (m, 1 H) 2.14 (br. s., 1 H) 2.01 (d, J = 8.84 Hz, 1 H) 1.91 (br. s., 1 H) 1.68 - 1.81 (m, 1 H) LCMS: [M+1] = 420/422/424, rt = 1.73 min. Example 19: 3-((1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3 - dihydro-1H-benzo[d]imidazole-5-carboxylic acid Methyl 3-((1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3 -dihydro-1H- benzo[d]imidazole-5-carboxylate A mixture of methyl 2-oxo-3-(pyrrolidin-3-ylmethyl)-2,3-dihydro-1H- benzo[d]imidazole-5-carboxylate hydrochloride (50.0 mg, 0.160 mmol), 2,4- dichlorobenzoic acid (36.8 mg, 0.193 mmol) HBTU (73.0 mg, 0.193 mmol) and DIPEA (112 µL, 0.642 mmol) in chloroform (5 mL) was stirred at room temperature for 16 h. The contents were treated with 5% Na 2 CO 3 and extracted with CHCl 3 (3x). The organic layers were filtered through a cotton plug, reduced in volume with a stream of N 2 and then purified by automated normal-phase chromatography (0-20% MeOH/DCM, 4 g silica gel cartridge) to give methyl 3-((1-(2,4- dichlorobenzoyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3-dihydro-1H -benzo[d]imidazole-5- carboxylate (55.6 mg, 0.124 mmol, 77.3% yield) as a colorless gum. Two amide conformers by 1 H NMR -- one peak by LCMS 1 H NMR (400 MHz, DMSO-d6) δ ppm 11.36 (br. s., 1 H) 7.67 - 7.80 (m, 3 H) 7.42 - 7.55 (m, 2 H) 7.09 (dd, J = 14.91, 8.08 Hz, 1 H) 3.94 - 3.99 (m, 1 H) 3.87 (d, J = 7.07 Hz, 1 H) 3.84 (d, J = 2.02 Hz, 3 H) 3.56 - 3.69 (m, 2 H) 3.44 (d, J = 12.38 Hz, 1 H) 2.96 - 3.29 (m, 2 H) 1.86 - 2.01 (m, 1 H) 1.64 - 1.79 (m, 1 H) LCMS: [M+1] = 448/450/452, rt = 2.27 min. 3-((1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3 -dihydro-1H- benzo[d]imidazole-5-carboxylic acid To a suspension of methyl 3-((1-(2,4-dichlorobenzoyl)pyrrolidin-3-yl)methyl)-2-oxo- 2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (55.6 mg, 0.124 mmol) in methanol (5 mL) was added 1 N NaOH (1.24 mL, 1.24 mmol). The resulting mixture was stirred at 60 °C for 46 h. The solvent was removed under a stream of N 2 , and the residue taken up in water and filtered through a syringe filter. The solution was acidified by addition of 6 N HCl and stirred for 18 h. The solid was collected by filtration, washed with water and dried under vacuum to give 3-((1-(2,4- dichlorobenzoyl)pyrrolidin-3-yl)methyl)-2-oxo-2,3-dihydro-1H -benzo[d]imidazole-5- carboxylic acid (31.4 mg, 0.0723 mmol, 58.3% yield) as a white solid. 1 H NMR shows two amide conformers — one peak by LCMS. 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.74 (br. s., 1 H) 11.27 - 11.34 (m, 1 H) 7.64 - 7.79 (m, 3 H) 7.43 - 7.54 (m, 2 H) 7.06 (dd, J = 14.65, 8.08 Hz, 1 H) 3.82 - 4.00 (m, 2 H) 3.41 - 3.69 (m, 2 H) 2.96 - 3.31 (m, 2 H) 2.65 - 2.80 (m, 1 H) 1.86 - 2.04 (m, 1 H) 1.63 - 1.80 (m, 1 H) LCMS: [M+1] = 420/422/424, rt = 1.96 min. IP6K1 IC50 Values of Representative Compounds of Formula (IA) and Formula (IB) Representative IP6K1 IC 50 values of compounds of formula (IA) and formula (IB) are provided in Table 1 and Table 2.
REFERENCES Chakraborty A, Koldobskiy MA, Bello NT, et al. Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain. Cell. 2010;143(6):897-910. Chakraborty A, Latapy C, Xu J, Snyder SH, Beaulieu J-M. Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways. Mol Psychiatry.2014; 19:284-293. Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther.2015;148:114-131. Beaulieu JM. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci. 2012;37(1):7-16. Tan HY, Chen AG, Kolachana B, et al. Effective connectivity of AKT1- mediated dopaminergic working memory networks and pharmacogenetics of anti- dopaminergic treatment. Brain.2012;135(5):1436-1445. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet. 2004;36(2):131-137. Bhat R V., Andersson U, Andersson S, Knerr L, Bauer U, Sundgren- Andersson AK. The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning? Perry G, Avila J, Moreira PI, Sorensen AA, Tabaton M, eds. J Alzheimer’s Dis.2018;64(s1):S547-S554. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci.2003;24(9):441-443. Beaulieu J-M, Marion S, Rodriguiz RM, et al. A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior. Cell.2008;132(1):125-136. Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry. 2000;61 Suppl 9:35-40. Le Roy V, Delmas Y, Verdoux H. Chronic renal complications induced by lithium. Encephale.2009;35(6):605-610. Pan JQ, Lewis MC, Ketterman JK, et al. AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in Mice. Neuropsychopharmacology. 2011;36(7):1397-1411. Gould TD, O’Donnell KC, Picchini AM, Manji HK. Strain Differences in Lithium Attenuation of d-Amphetamine-Induced Hyperlocomotion: A Mouse Model for the Genetics of Clinical Response to Lithium. Neuropsychopharmacology. 2007;32(6):1321-1333. Miller, E., et al., Type 2 diabetes: Evolving concepts and treatment. Cleve Clin J Med, 2019.86(7): p. 494-504. Petersen, M.C. and G.I. Shulman, Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev, 2018.98(4): p.2133-2223. Hickson, R.P., A.L. Cole, and S.B. Dusetzina, Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. J Manag Care Spec Pharm, 2019.25(1): p.72-79. Marks, D.H., Drug utilization, safety and clinical use of Actos and Avandia. Int J Risk Saf Med, 2013.25(1): p.39-51. Fayard, E., et al., Protein Kinase B (PKB/Akt), a Key Mediator of the PI3K Signaling Pathway. Phosphoinositide 3-Kinase in Health and Disease, Vol 1, 2010. 346: p.31-56. Ghoshal, S., et al., TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway. Mol Metab, 2016.5(10): p.903-17. Barclay, R.D., et al., Ingestion of lean meat elevates muscle inositol hexakisphosphate kinase 1 protein content independent of a distinct post-prandial circulating proteome in young adults with obesity. Metabolism, 2019: p.153996. Zhu, Q., et al., Adipocyte-specific deletion of Ip6k1 reduces diet-induced obesity by enhancing AMPK-mediated thermogenesis. J Clin Invest, 2016. Cokorinos, E.C., et al., Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice. Cell Metab, 2017.25(5): p.1147-1159 e10. Myers, R.W., et al., Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science, 2017.357(6350): p. 507-511. Steneberg, P., et al., PAN-AMPK activator O 3 0 4 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight, 2018.3(12). Gu, C., et al., KO of 5-InsP7 kinase activity transforms the HCT116 colon cancer cell line into a hypermetabolic, growth-inhibited phenotype. Proc Natl Acad Sci USA, 2017.114(45): p.11968-11973. Szijgyarto, Z., et al., Influence of inositol pyrophosphates on cellular energy dynamics. Science, 2011.334(6057): p.802-5. Sun, D., et al., Oncostatin M (OSM) protects against cardiac ischaemia/reperfusion injury in diabetic mice by regulating apoptosis, mitochondrial biogenesis and insulin sensitivity. J Cell Mol Med, 2015.19(6): p.1296-307. Szendroedi, J., et al., Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med, 2007. 4(5): p. e154. Koliaki, C. and M. Roden, Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol, 2013. 379(1-2): p.35-42. Muller, F., et al., Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell, 2009.139(6): p.1143-56. Labberton, L., et al., Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. Nat Commun, 2016.7: p.12616. Ghosh, S., et al., Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. Blood, 2013.122(8): p.1478-1486. Booth, G.L., et al., Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet, 2006.368(9529): p.29-36. Authors/Task Force, M., et al., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J, 2013.34(39): p.3035-87. International PCT Patent Application Publication No. WO2018182051 for IP6K INHIBITORS to Terao et al., published October 4, 2018. Although the foregoing subject matter has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be understood by those skilled in the art that certain changes and modifications can be practiced within the scope of the appended claims.
Next Patent: CATHETER SYSTEM FOR VALVULOPLASTY PROCEDURE